Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
  • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
  • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
  • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
  • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
  • A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
  • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
  • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
  • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
  • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
  • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
  • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
  • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
  • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
  • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
  • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Definitions

• the field of the invention relates generally to an antibody-drug conjugate comprising an antibody directly conjugated to one or more silvestrol molecules.
• Silvestrol and silvestrol derivatives refer to a family of antibacterial and antitumor agents (Lucas, D M. et al (2009) Blood, 113, 4656-4666; Alinari, L. et al (2012) Clin.
• Silvestrol (CAS:697235-38-4) is named as methyl (lR,2R,3S,3aR,8bS)-6- (((2S,3R,6R)-6-((R)-l,2-dihydroxyethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8- methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-
• Antibody-drug conjugates also known as ADC or immunoconjugates, are targeted chemo-therapeutic molecules, combining the properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to the antigen-expressing tumor cells, thereby enhancing their anti -tumor activity.
• Successful antibody-drug conj ugate development for a given target antigen depends on optimization of antibody selection, linker stability, cytotoxic drug potency and mode of linker-drug conjugation to the antibody.
• selective antibody-drug conjugates are characterized by at least one or more of the following: (i) an antibody-drug conjugate formation method wherein the antibody retains sufficient specificity to target antigens and wherein the drug efficacy is maintained; (ii) antibody-drug conjugate stability sufficient to limit drug release in the blood and concomitant damage to non-targeted cells; (iii) sufficient cell membrane transport efficiency (endocytosis) to achieve a therapeutic intracellular antibody-drug conjugate concentration; (iv) sufficient intracellular drug release from the antibody-drug conjugate sufficient to achieve a therapeutic drug concentration; and (v) drug cytotoxicity in nanomolar or sub-nanomolar amounts.
• Antibody-drug conjugates allow for the targeted delivery of a drug moiety to a tumor, and, in some embodiments intracellular accumulation therein, where systemic administration of unconjugated drugs may result in unacceptable levels of toxicity to normal cells (Polakis P. (2005) Current Opinion in Pharmacology 5: 382-387).
• Antibody-drug conjugates are targeted chemotherapeutic molecules which combine properties of both antibodies and cytotoxic drugs by targeting potent cytotoxic drugs to antigen-expressing tumor cells (Teicher, B.A. (2009) Current Cancer Drug Targets 9: 982- 1004), thereby enhancing the therapeutic index by maximizing efficacy and minimizing off- target toxicity (Carter, P.J. and Senter P.D. (2008) The Cancer Jour. 14(3): 154-169; Chari, R.V. (2008) Acc. Chem. Res. 41 : 98-107.
• Antibodies have been developed that provide for site-specific conjugation of a drug to the antibody through cysteine substitutions at sites where the engineered cysteines are available for conjugation but do not perturb immunoglobulin folding and assembly or alter antigen binding and effector functions (Junutula, et al, 2008b Nature Biotech., 26(8): 925- 932; Dornan et al. (2009) Blood 1 14(13):2721-2729; US 7521541 ; US 7723485;
• THIOMABTM antibodies can then be conjugated to cytotoxic drugs through the engineered cysteine thiol groups to obtain THIOMABTM drug conjugates (TDC) with uniform stoichiometry (e.g., up to 2 drugs per antibody in an antibody that has a single engineered cysteine site).
• TDC drug conjugates
• Studies with multiple antibodies against different antigens have shown that TDCs are as efficacious as conventional antibody-drug conjugate in xenograft models and are tolerated at higher doses in relevant preclinical models.
• THIOMAB antibodies have been engineered for drug attachment at different locations of the antibody (e.g., specific amino acid positions (i.e., sites) within the light chain-Fab, heavy chain-Fab and heavy chain-Fc).
• the in vitro and in vivo stability, efficacy and PK properties of THIOMABTM antibodies provide a unique advantage over conventional antibody-drug conjugates due to their homogeneity and site-specific conjugation to cytotoxic drugs.
• linkers may be labile in the blood stream, thereby releasing unacceptable amounts of the drug prior to internalization in a target cell (Khot, A. et al (2015) Bioanalysis 7(13): 1633-1648).
• Other linkers may provide stability in the bloodstream, but intracellular release effectiveness may be negatively impacted.
• Linkers that provide for desired intracellular release typically have poor stability in the bloodstream.
• bloodstream stability and intracellular release are typically inversely related.
• aggregate formation is generally positively correlated to the number of equivalents of drug moiety and derivatives thereof conjugated to the carrier- antibody.
• formed aggregates must be removed for therapeutic applications.
• drug loading-mediated aggregate formation decreases antibody- drug conjugate yield and can render process scale-up difficult. Accordingly, there is a continuing need for improved efficacious antibody-drug conjugates that provide for optimized safety and efficacy.
• the present disclosure is generally directed to antibody-drug conjugates comprising an antibody linked by conjugation to one or more silvestrol derivatives.
• the present disclosure is further directed to silvestrol derivative intermediate compositions comprising a leaving group.
• Such intermediate compositions are suitable substrates for formation of antibody-drug conjugates wherein an antibody may be covalently bound to silvestrol derivative, through a linker or linking moiety.
• the present disclosure is further directed to use of such an antibody-silvestrol conjugate in the treatment of an illness, in particular cancer.
• silvestrol refers to the silvestrol derivative compounds encompassed by the present disclosure.
• the invention includes an antibody-drug conjugate compound comprising an antibody covalently attached through a linker to a silvestrol drug moiety, selected from Formulas la and lb:
• R a is a group selected from CH 3 0, CN, N0 2 , and CI;
• L is a linker
• p is an integer from 1 to 8.
• Ab is an antibody which binds to one or more tumor-associated antigens or cell- surface receptors.
• the invention includes a pharmaceutical composition
• a pharmaceutical composition comprising the antibody-drug conjugate compound selected from Formulas la and lb, and a pharmaceutically acceptable diluent, carrier or excipient.
• the invention includes the use of the antibody-drug conjugate compound selected from Formulas la and lb in the manufacture of a medicament for the treatment of cancer in a mammal.
• the invention includes a method of treating cancer comprising administering to a patient the pharmaceutical composition comprising the antibody-drug conjugate compound selected from Formulas la and lb.
• the invention includes the antibody-drug conjugate compound selected from
• Formulas la and lb for use in a method for treating cancer are listed in Table 1.
• the invention includes an article of manufacture comprising the pharmaceutical composition comprising the antibody-drug conjugate compound selected from Formulas la and lb, a container, and a package insert or label indicating that the pharmaceutical composition can be used to treat cancer.
• the invention includes a silvestrol-linker intermediate compound of Formula II:
• R a is a group selected from CH 3 0, CN, N0 2 , and CI;
• R 1 is selected from -OCH 3 and L-X;
• R 2 is selected from -CH(OH)CH 2 OH, and L-X
• L is a linker
• X comprises a reactive functional group selected from maleimide, thiol, amino, bromide, bromoacetamido, iodoacetamido, p-toluenesulfonate, iodide, hydroxyl, carboxyl, pyridyl disulfide, and N-hydroxysuccinimide.
• the invention includes a method of making an antibody-drug conjugate compound selected from Formulas la and lb, the method comprising reacting an antibody with a silvestrol-linker intermediate compound of Formula II.
• Figure 1 A shows a plot of in vitro cell viability of SK-BR-3 cells treated with Thio anti-Her2 7C2 LC-K149C-MC-vc-PAB-Silvestrol-amine, ADC-103, Thio Hu Anti-CD22 10F4v3 HC:A140C amino silvestrol analog, ADC-105, non-target control, and Thio Hu Anti- Her2 7C2 HC:A140C amino silvestrol analog, ADC-106
• Figure IB shows a plot of in vitro cell viability of KPL-4 cells treated with Thio anti- Her2 7C2 LC-K149C-MC-vc-PAB-Silvestrol-amine, ADC-103, Thio Hu Anti-CD22 10F4v3 HC:A140C amino silvestrol analog, ADC-105, non-target control, and Thio Hu Anti-Her2 7C2 HC:A140C amino silvestrol analog, ADC-106.
• Figure 1C shows a plot of in vitro cell viability of Bjab-luc cells treated with Thio anti-Her2 7C2 LC-K149C-MC-vc-PAB-Silvestrol-amine, ADC-103, and Thio anti-CD22 LC-K149C-MC-vc-PAB-Silvestrol-amine, 6 mg/kg IV once, ADC-104.
• Figure ID shows a plot of in vitro cell viability of WSU-DLCL2 cells treated with Thio anti-Her2 7C2 LC-K149C-MC-vc-PAB-Silvestrol-amine, ADC-103, and Thio anti- CD22 LC-K149C-MC-vc-PAB-Silvestrol-amine, ADC-104, 6 mg/kg IV once,.
• Figure 2 shows the efficacy of antibody-drug conjugates in a plot of the in vivo fitted tumor volume change over time in Bjab-luc human xenograft model in CB-17 Fox Chase SCID mice.
• Figure 3 shows the efficacy of antibody-drug conjugates in a plot of the in vivo fitted tumor volume change over time in in KPL4 human mammary xenograft model in scid beige mice.
• Figure 4 shows the efficacy of antibody-drug conjugates in a plot of the in vivo fitted tumor volume change over time in Bjab-luc human xenograft model in CB-17 Fox Chase SCID mice.
• Figure 5 shows the efficacy of antibody-drug conjugates in a plot of the in vivo fitted tumor volume change over time in Bjab-luc human xenograft model in CB-17 Fox Chase SCID mice.
• Binding affinity refers to the strength of the sum total of noncovalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless indicated otherwise, as used herein, "binding affinity” refers to intrinsic binding affinity which reflects a 1 : 1 interaction between members of a binding pair (e.g., antibody and antigen).
• the affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (Kd). Affinity can be measured by common methods known in the art, including those described herein. Specific illustrative and exemplary embodiments for measuring binding affinity are described in the following.
• antibody herein is used in the broadest sense and specifically covers monoclonal antibodies, polyclonal antibodies, dimers, multimers, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments, so long as they exhibit the desired biological activity (Miller et al. (2003) Jour, of Immunology 170:4854-4861). Antibodies may be murine, human, humanized, chimeric, or derived from other species. An antibody is a protein generated by the immune system that is capable of recognizing and binding to a specific antigen. (Janeway, C, Travers, P., Walport, M., Shlomchik (2001) Immuno Biology, 5th Ed., Garland Publishing, New York).
• a target antigen generally has numerous binding sites, also called epitopes, recognized by CDRs on multiple antibodies. Each antibody that specifically binds to a different epitope has a different structure. Thus, one antigen may have more than one corresponding antibody.
• An antibody includes a full-length immunoglobulin molecule or an immunologically active portion of a full-length
• immunoglobulin molecule i.e., a molecule that contains an antigen binding site that immunospecifically binds an antigen of a target of interest or part thereof, such targets including but not limited to, cancer cell or cells that produce autoimmune antibodies associated with an autoimmune disease.
• the immunoglobulin disclosed herein can be of any type (e.g., IgG, IgE, IgM, IgD, and IgA), class (e.g., IgGl , IgG2, IgG3, IgG4, IgAl and IgA2) or subclass of immunoglobulin molecule.
• the immunoglobulins can be derived from any species. In one aspect, however, the immunoglobulin is of human, murine, or rabbit origin.
• Antibody fragments comprise a portion of a full length antibody, generally the antigen binding or variable region thereof.
• Examples of antibody fragments include Fab, Fab', F(ab')2, and Fv fragments; diabodies; linear antibodies; minibodies (Olafsen et al.
• monoclonal antibody refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. Monoclonal antibodies are highly specific, being directed against a single antigenic site. Furthermore, in contrast to polyclonal antibody preparations which include different antibodies directed against different determinants (epitopes), each monoclonal antibody is directed against a single determinant on the antigen. In addition to their specificity, the monoclonal antibodies are advantageous in that they may be synthesized uncontaminated by other antibodies.
• the modifier "monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method.
• the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al. (1975) Nature 256:495, or may be made by recombinant DNA methods (see for example: US 4816567; US 5807715).
• the monoclonal antibodies may also be isolated from phage antibody libraries using the techniques described in Clackson et al. (1991) Nature, 352:624-628; Marks et al. (1991) J. Mol. Biol, 222:581 -597; for example.
• the monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired biological activity (US 4816567; and Morrison et al. (1984) Proc. Natl. Acad. Sci. USA, 81 : 6851 -6855).
• Chimeric antibodies of interest herein include "primatized" antibodies comprising variable domain antigen-binding sequences derived from a non-human primate (e.g., Old World Monkey, Ape, etc.) and human constant region sequences.
• an “intact antibody” herein is one comprising a VL and VH domains, as well as a light chain constant domain (CL) and heavy chain constant domains, CHI, CH2 and CH3.
• the constant domains may be native sequence constant domains (e.g., human native sequence constant domains) or amino acid sequence variant thereof.
• the intact antibody may have one or more "effector functions" which refer to those biological activities attributable to the Fc constant region (a native sequence Fc region or amino acid sequence variant Fc region) of an antibody. Examples of antibody effector functions include CI q binding;
• immunoglobulin antibodies can be assigned to different "classes.” There are five major classes of intact immunoglobulin antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into "subclasses" (isotypes), e.g., IgGl, IgG2, IgG3, IgG4, IgA, and IgA2.
• the heavy -chain constant domains that correspond to the different classes of antibodies are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
• the subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known. Ig forms include hinge-modifications or hingeless forms (Roux et al. (1998) J. Immunol. 161 :4083-4090; Lund et al. (2000) Eur. J. Biochem. 267:7246-7256; US 2005/0048572; US 2004/0229310).
• cyste engineered antibody or “cysteine engineered antibody variant” is an antibody in which one or more residues of an antibody are substituted with cysteine residues.
• the thiol group(s) of the cysteine engineered antibodies can be conjugated to silvestrol to form a THIOMABTM antibody (i.e., a
• TDC THIOMABTM drug conjugate
• the drug is a silvestrol derivative
• the substituted residues occur at accessible sites of the antibody.
• reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to the drug moiety to create an immunoconjugate, as described further herein.
• a THIOMABTM antibody may be an antibody with a single mutation of a non- cysteine native residue to a cysteine in the light chain (e.g., G64C, K149C or R142C according to Kabat numbering) or in the heavy chain (e.g., D 101 C or V184C or T205C according to Kabat numbering).
• a THIOMABTM antibody has a single cysteine mutation in either the heavy or light chain such that each full-length antibody (i.e., an antibody with two heavy chains and two light chains) has two engineered cysteine residues. Cysteine engineered antibodies and preparatory methods are disclosed by US 2012/0121615 Al (incorporated by reference herein in its entirety).
• cancer refers to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth/proliferation.
• Examples of cancer include, but are not limited to, carcinoma, lymphoma (e.g., Hodgkin's and non- Hodgkin's lymphoma), blastoma, sarcoma, and leukemia.
• cancers include acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelogenous leukemia (CML), chronic myelomonocytic leukemia, acute promyelocytic leukemia (APL), chronic myeloproliferative disorder, thrombocytic leukemia, precursor B- cell acute lymphoblastic leukemia (pre-B-ALL), precursor T-cell acute lymphoblastic leukemia (preT-ALL), multiple myeloma (MM), mast cell disease, mast cell leukemia, mast cell sarcoma, myeloid sarcomas, lymphoid leukemia, and undifferentiated leukemia.
• the cancer is myeloid leukemia.
• the cancer is acute myeloid leukemia (AML).
• chimeric antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.
• the "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain.
• the heavy chain constant domains that correspond to the different classes of immunoglobulins are called ⁇ , ⁇ , ⁇ , ⁇ , and ⁇ , respectively.
• Antibody effector functions refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: Clq binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.
• an "effective amount" of an agent refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.
• epitope refers to the particular site on an antigen molecule to which an antibody binds.
• the particular site on an antigen molecule to which an antibody binds is determined by hydroxyl radical footprinting.
• Fc region herein is used to define a C-terminal region of an
• immunoglobulin heavy chain that contains at least a portion of the constant region.
• the term includes native sequence Fc regions and variant Fc regions.
• a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain.
• the C-terminal lysine (Lys447) of the Fc region may or may not be present.
• numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat et al, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.
• FR Framework or "FR” refers to variable domain residues other than hypervariable region (FFVR) residues.
• the FR of a variable domain generally consists of four FR domains: FR1 , FR2, FR3, and FR4. Accordingly, the FFVR and FR sequences generally appear in the following sequence in VH (or VL): FR1 -H1 (L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.
• full length antibody “intact antibody,” and “whole antibody” are used herein interchangeably to refer to an antibody having a structure substantially similar to a native antibody structure or having heavy chains that contain an Fc region as defined herein.
• host cell "host cell line,” and “host cell culture” are used interchangeably.
• Host cells include “transformants” and “transformed cells,” which include the primary transformed cell and progeny derived therefrom without regard to the number of passages.
• Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein.
• a "human antibody” is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody- encoding sequences. This definition of a human antibody specifically excludes a humanized antibody comprising non-human antigen-binding residues.
• a "human consensus framework” is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences.
• the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences.
• the subgroup of sequences is a subgroup as in Kabat et al, Sequences of Proteins of Immunological Interest, Fifth Edition, NIH Publication 91 -3242, Bethesda MD (1991), vols. 1 -3.
• the subgroup is subgroup kappa I as in Kabat et al., supra.
• the subgroup is subgroup III as in Kabat et al., supra.
• a “humanized” antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs.
• a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody.
• a humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.
• a "humanized form" of an antibody, e.g., a non-human antibody refers to an antibody that has undergone humanization.
• variable region refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen.
• the variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs).
• FRs conserved framework regions
• HVRs hypervariable regions
• antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See, e.g., Portolano et al, J. Immunol. 150: 880-887 (1993); Clarkson et al, Nature 352:624-628 (1991).
• vector refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked.
• the term includes the vector as a self- replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced.
• Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors.”
• hypervariable region refers to each of the regions of an antibody variable domain which are hypervariable in sequence and/or form structurally defined loops ("hypervariable loops").
• native four-chain antibodies comprise six HVRs; three in the VH (HI, H2, H3), and three in the VL (LI, L2, L3).
• HVRs generally comprise amino acid residues from the hypervariable loops and/or from the "complementarity determining regions" (CDRs), the latter being of highest sequence variability and/or involved in antigen recognition.
• CDRs complementarity determining regions
• Exemplary hypervariable loops occur at amino acid residues 26-32 (LI), 50-52 (L2), 91 -96 (L3), 26-32 (HI), 53-55 (H2), and 96-101 (H3).
• Exemplary CDRs CDR-L1 , CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 of LI, 50-56 of L2, 89-97 of L3, 31 -35B of HI, 50-65 of H2, and 95-102 of H3.
• CDRs generally comprise the amino acid residues that form the hypervariable loops.
• CDRs also comprise "specificity determining residues,” or "SDRs,” which are residues that contact antigen. SDRs are contained within regions of the CDRs called abbreviated-CDRs, or a- CDRs.
• Exemplary a-CDRs (a-CDR-Ll, a-CDR-L2, a-CDR-L3, a-CDR-Hl, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 of LI, 50-55 of L2, 89-96 of L3, 31-35B of HI, 50-58 of H2, and 95-102 of H3.
• HVR residues and other residues in the variable domain are numbered herein according to Kabat et al., supra.
• mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats).
• domesticated animals e.g., cows, sheep, cats, dogs, and horses
• primates e.g., humans and non-human primates such as monkeys
• rabbits e.g., mice and rats
• rodents e.g., mice and rats.
• the individual or subject is a human.
• an “isolated antibody” is one which has been separated from a component of its natural environment.
• an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion exchange or reverse phase HPLC).
• electrophoretic e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis
• chromatographic e.g., ion exchange or reverse phase HPLC
• Native antibodies refer to naturally occurring immunoglobulin molecules with varying structures.
• native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CHI, CH2, and CH3).
• VH variable region
• VL variable region
• the light chain of an antibody may be assigned to one of two types, called kappa ( ⁇ ) and lambda ( ⁇ ), based on the amino acid sequence of its constant domain.
• package insert is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.
• Percent (%) amino acid sequence identity with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared.
• % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2.
• the ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office,
• the ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code.
• the ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.
• the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B is calculated as follows: 100 times the fraction X/Y where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B.
• pharmaceutical formulation refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.
• a “pharmaceutically acceptable carrier” refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject.
• a pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.
• beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total), whether detectable or undetectable.
• Treatment can also mean prolonging survival as compared to expected survival if not receiving treatment.
• Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.
• the term "therapeutically effective amount” refers to an amount of a drug effective to treat a disease or disorder in a mammal.
• the therapeutically effective amount of the drug may reduce the number of cancer cells; reduce the tumor size; inhibit (i.e., slow to some extent and preferably stop) cancer cell infiltration into peripheral organs; inhibit (i.e., slow to some extent and preferably stop) tumor metastasis; inhibit, to some extent, tumor growth; and/or relieve to some extent one or more of the symptoms associated with the cancer.
• the drug may prevent growth and/or kill existing cancer cells, it may be cytostatic and/or cytotoxic.
• efficacy can, for example, be measured by assessing the time to disease progression (TTP) and/or determining the response rate (RR).
• cancer refers to or describe the physiological condition in mammals that is typically characterized by unregulated cell growth.
• a “tumor” comprises one or more cancerous cells. Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia or lymphoid malignancies. More particular examples of such cancers include squamous cell cancer (e.g., epithelial squamous cell cancer), lung cancer including small- cell lung cancer, non-small cell lung cancer
• NSCLC adenocarcinoma of the lung and squamous carcinoma of the lung, cancer of the peritoneum, hepatocellular cancer, gastric or stomach cancer including gastrointestinal cancer, pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as head and neck cancer.
• gastrointestinal cancer pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, breast cancer, colon cancer, rectal cancer, colorectal cancer, endometrial or uterine carcinoma, salivary gland carcinoma, kidney or renal cancer, prostate cancer, vulval cancer, thyroid cancer, hepatic carcinoma, anal carcinoma, penile carcinoma, as well as
• leaving group refers to a sulfhydryl moiety that leaves in the course of a chemical reaction involving the groups as described herein.
• alkyl refers to a saturated linear or branched-chain monovalent hydrocarbon radical of one to twelve carbon atoms (Ci-C ), wherein the alkyl radical may be optionally substituted independently with one or more substituents described below.
• an alkyl radical is one to eight carbon atoms (Ci-C 8 ), or one to six carbon atoms (Ci-Ce).
• alkyl groups include, but are not limited to, methyl (Me, -CH 3 ), ethyl (Et, -CH 2 CH 3 ), 1 -propyl (n-Pr, n-propyl, -CH 2 CH 2 CH 3 ), 2-propyl (i-Pr, i-propyl, -CH(CH 3 ) 2 ), 1 -butyl (n-Bu, n-butyl, -CH 2 CH 2 CH 2 CH 3 ), 2-methyl-l -propyl (i- Bu, i-butyl, -CH 2 CH(CH 3 ) 2 ), 2-butyl (s-Bu, s-butyl, -CH(CH 3 )CH 2 CH 3 ), 2-methyl-2-propyl (t-Bu, t-butyl, -C(CH 3 ) 3 ), 1-pentyl (n-pentyl, -CH 2 CH 2 CH 2 CH 3 ), 2-pentyl (n
• alkylene refers to a saturated linear or branched-chain divalent hydrocarbon radical of one to twelve carbon atoms (Ci-Ci 2 ), wherein the alkylene radical may be optionally substituted independently with one or more substituents described below.
• an alkylene radical is one to eight carbon atoms (Ci-Cg), or one to six carbon atoms (Ci-Ce).
• alkylene groups include, but are not limited to, methylene (-CH 2 -), ethylene (-CH 2 CH 2 -), propylene (-CH 2 CH 2 CH 2 -), and the like.
• alkynyl refers to a linear or branched monovalent hydrocarbon radical of two to eight carbon atoms (C 2 -C 8 ) with at least one site of unsaturation, i.e., a carbon-carbon, sp triple bond, wherein the alkynyl radical may be optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, ethynyl (-OCH), propynyl (propargyl, -CH 2 C ⁇ CH), and the like.
• alkynylene refers to a linear or branched divalent hydrocarbon radical of two to eight carbon atoms (C 2 -C 8 ) with at least one site of unsaturation, i.e., a carbon-carbon, sp triple bond, wherein the alkynylene radical may be optionally substituted independently with one or more substituents described herein. Examples include, but are not limited to, ethynylene (-C ⁇ C-), propynylene (propargylene, -CH 2 C ⁇ C-), and the like.
• carrier refers to a monovalent non-aromatic, saturated or partially unsaturated ring having 3 to 12 carbon atoms (C3-C12) as a monocyclic ring or 7 to 12 carbon atoms as a bicyclic ring.
• Bicyclic carbocycles having 7 to 12 atoms can be arranged, for example, as a bicyclo [4,5], [5,5], [5,6] or [6,6] system, and bicyclic carbocycles having 9 or 10 ring atoms can be arranged as a bicyclo [5,6] or [6,6] system, or as bridged systems such as bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane and bicyclo[3.2.2]nonane.
• Spiro carbocyclyl moieties are also included within the scope of this definition. Examples of spiro carbocyclyl moieties include
• Examples of monocyclic carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopent-l-enyl, 1-cyclopent- 2-enyl, l-cyclopent-3-enyl, cyclohexyl, 1-cyclohex-l-enyl, l-cyclohex-2-enyl, l-cyclohex-3- enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and the like.
• Carbocyclyl groups are optionally substituted independently with one or more substituents described herein.
• aryl as used herein alone or as part of another group denotes optionally substituted homocyclic aromatic groups, preferably monocyclic or bicyclic groups containing from 5 to 20 carbons, from 5 to 10 carbons, or from 5 to 6 carbons in the ring portion, including, but not limited to, phenyl, biphenyl, naphthyl, substituted phenyl, substituted biphenyl or substituted naphthyl.
• the aryl moieties may optionally comprise one or more hetero atoms selected from O, S and N.
• Such heteroaromatics may comprise 1 or 2 nitrogen atoms, 1 or 2 sulfur atoms, 1 or 2 oxygen atoms, and combinations thereof, in the ring, wherein the each hetero atom is bonded to the remainder of the molecule through a carbon.
• Non limiting exemplary groups include pyridine, pyrazine, pyrimidine, pyrazole, pyrrole, imidazole, thiophene, thiopyrrilium, parathiazine, indole, purine, benzimidazole, quinolone, and phenothiazine.
• Non-limiting exemplary substituents include one or more of the following groups: alkyl, alkoxy, acyl, acyloxy, alkenyl, alkenoxy, aryl, aryloxy, amino, amido, acetal, carbamyl, carbocyclo, cyano, ester, ether, halogen, heterocyclo, hydroxy, keto, ketal, phospho, nitro, and thio.
• substituted moieties described herein are moieties such as alkyl and aryl which are substituted with at least one atom other than carbon, including moieties in which a carbon chain atom is substituted with a hetero atom such as nitrogen, oxygen, silicon, phosphorous, boron, sulfur, or a halogen atom.
• substituents include, but are not limited to, halogen, heterocyclo, alkoxy, alkenoxy, alkynoxy, aryloxy, hydroxy, keto, acyl, acyloxy, nitro, tertiary amino, amido, nitro, cyano, thio, sulfinate, sulfonamide, ketals, acetals, esters and ethers.
• halogen as used herein alone or as part of another group refer to chlorine, bromine, fluorine, and iodine.
• an antibody is humanized.
• an antibody comprises HVRs as in any of the embodiments of the disclosure, and further comprises a human acceptor framework, e.g. a human immunoglobulin framework or a human consensus framework.
• the human acceptor framework is the human VL kappa I consensus (VLKI) framework and/or the VH framework VH1.
• the human acceptor framework is the human VL kappa I consensus (VLKI) framework and/or the VH framework VH1 comprising any one of the following mutations.
• the antibody comprises a VH as in any of the embodiments provided herein, and a VL as in any of the embodiments provided herein.
• an antibody according to any of the embodiments herein is a monoclonal antibody, including a human antibody.
• an antibody is an antibody fragment, e.g., a Fv, Fab, Fab', scFv, diabody, or F(ab')2 fragment.
• the antibody is a substantially full length antibody, e.g., an IgGl antibody, IgG2a antibody or other antibody class or isotype as defined herein.
• an antibody according to any of the embodiments herein may incorporate any of the features, singly or in combination, as described herein.
• an antibody provided herein has a dissociation constant (Kd) of ⁇ l uM, ⁇ 100 nM, ⁇ 50 nM, ⁇ 10 nM, ⁇ 5 nM, ⁇ 1 nM, ⁇ 0.1 nM, ⁇ 0.01 nM, or ⁇ 0.001 nM, and optionally is > 10 "13 M. (e.g. 10 "8 M or less, e.g. from 10 "8 M to 10 "13 M, e.g. , from 10 "9 M to 10 "13 M).
• Kd dissociation constant
• Kd is measured by a radiolabeled antigen binding assay (RIA) performed with the Fab version of an antibody of interest and its antigen as described by the following assay.
• Solution binding affinity of Fabs for antigen is measured by equilibrating Fab with a minimal concentration of ( 125 I)-labeled antigen in the presence of a titration series of unlabeled antigen, then capturing bound antigen with an anti-Fab antibody-coated plate
• MICROTITER ® multi-well plates (Thermo Scientific) are coated ovemight with 5 ⁇ g/ml of a capturing anti-Fab antibody (Cappel Labs) in 50 mM sodium carbonate (pH 9.6), and subsequently blocked with 2% (w/v) bovine serum albumin in PBS for two to five hours at room temperature (approximately 23 °C).
• a non-adsorbent plate (Nunc #269620) 100 pM or 26 pM [ 125 I] -antigen are mixed with serial dilutions of a Fab of interest (e.g., consistent with assessment of the anti-VEGF antibody, Fab-12, in Presta et al, Cancer Res. 57:4593- 4599 (1997)).
• the Fab of interest is then incubated overnight; however, the incubation may continue for a longer period (e.g., about 65 hours) to ensure that equilibrium is reached. Thereafter, the mixtures are transferred to the capture plate for incubation at room
• Kd is measured using surface plasmon resonance assays using a BIACORE ® -2000, BIACORE ® -T200 or a BIACORE ® -3000 (BIAcore, Inc., Piscataway, NJ) at 25°C with immobilized antigen CM5 chips at -10 response units (RU).
• CM5 carboxymethylated dextran biosensor chips
• EDC N-ethyl-N'- (3-dimethylaminopropyl)-carbodiimide hydrochloride
• NHS N- hydroxysuccinimide
• Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 g ml (-0.2 ⁇ ) and/or HBS-P (0.01 M Hepes pH7.4, 0.15M NaCl, 0.005% Surfactant P20) before injection at a flow rate of 5 ul/minute and/or 30 ⁇ /minute to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups.
• an antibody provided herein is an antibody fragment.
• Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')2, Fv, and scFv fragments, and other fragments described herein.
• Fab fragment antigen binding protein
• Fab' fragment antigen binding protein
• Fab'-SH fragment antigen binding protein
• F(ab')2 fragment antigen binding protein
• scFv fragments fragment antigen binding protein fragments
• other fragments described herein For a review of certain antibody fragments, see Hudson et al. Nat. Med. 9: 129-134 (2003).
• scFv fragments see, e.g., Pluckthiin, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., (Springer-Verlag, New York), pp. 269-315 (1994); see also WO 1993/16185; and US 5571894 and US 5587,58.
• Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 404097; WO 1993/01161 ; Hudson et al., Nat. Med. 9: 129- 134 (2003); and Hollinger et al., Proc. Natl. Acad. Sci. USA 90: 6444-6448 (1993).
• Triabodies and tetrabodies are also described in Hudson et al, Nat. Med. 9: 129-134 (2003).
• Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody.
• a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., US 6248516).
• Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. E. coli or phage), as described herein.
• recombinant host cells e.g. E. coli or phage
• an antibody provided herein is a chimeric antibody.
• Certain chimeric antibodies are described, e.g., in US 4816567; and Morrison et al, Proc. Natl. Acad. Sci. USA, 81 :6851-6855 (1984)).
• a chimeric antibody comprises a non- human variable region (e.g. , a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey) and a human constant region.
• a chimeric antibody is a "class switched" antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.
• a chimeric antibody is a humanized antibody.
• a non-human antibody is humanized to reduce immunogenicity to humans, while retaining the specificity and affinity of the parental non-human antibody.
• a humanized antibody comprises one or more variable domains in which HVRs, e.g. , CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences.
• a humanized antibody optionally will also comprise at least a portion of a human constant region.
• some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g. , the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.
• Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the "best-fit" method (see, e.g. , Sims et al. J. Immunol. 151 :2296 (1993)); framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g. , Carter et al. Proc. Natl. Acad. Sci. USA, 89:4285 (1992); and Presta et al. J. Immunol , 151 :2623 (1993)); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g. , Almagro and Fransson, Front. Biosci.
• an antibody provided herein is a human antibody.
• Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk and van de Winkel, Curr. Opin. Pharmacol. 5 : 368-74 (2001) and Lonberg, Curr. Opin. Immunol. 20:450-459 (2008).
• Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous
• Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal antibodies have been described. (See, e.g. , Kozbor J. Immunol , 133: 3001 (1984); Brodeur et al., Monoclonal Antibody Production Techniques and Applications , pp. 51-63 (Marcel Dekker, Inc., New York, 1987); and Boerner et al, J. Immunol, 147: 86 (1991).) Human antibodies generated via human B-cell hybridoma technology are also described in Li et al, Proc. Natl. Acad. Sci. USA, 103: 3557-3562 (2006).
• Additional methods include those described, for example, in US 7189826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, Xiandai Mianyixue, 26(4):265-268 (2006) (describing human-human hybridomas).
• Human hybridoma technology Trioma technology
• Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described herein.
• Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g. , in
• repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter et al., Ann. Rev. Immunol , 12: 433-455 (1994).
• Phage typically display antibody fragments, either as single- chain Fv (scFv) fragments or as Fab fragments.
• scFv single-chain Fv
• Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas.
• the naive repertoire can be cloned (e.g.
• naive libraries can also be made synthetically by cloning unrearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement in vitro, as described by Hoogenboom and Winter, J. Mol. Biol , 227: 381 -388 (1992).
• Patent publications describing human antibody phage libraries include, for example: US Patent No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598,
• Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.
• an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody.
• the term "multispecific antibody” is used in the broadest sense and specifically covers an antibody comprising an antigen-binding domain that has polyepitopic specificity (i.e., is capable of specifically binding to two, or more, different epitopes on one biological molecule or is capable of specifically binding to epitopes on two, or more, different biological molecules).
• multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites.
• an antigen-binding domain of a multispecific antibody (such as a bispecific antibody) comprises two VH/VL units, wherein a first VH/VL unit specifically binds to a first epitope and a second VH/VL unit specifically binds to a second epitope, wherein each VH/VL unit comprises a heavy chain variable domain (VH) and a light chain variable domain (VL).
• Such multispecific antibodies include, but are not limited to, full length antibodies, antibodies having two or more VL and VH domains, antibody fragments such as Fab, Fv, dsFv, scFv, diabodies, bispecific diabodies and triabodies, antibody fragments that have been linked covalently or non-covalently.
• a VH/VL unit that further comprises at least a portion of a heavy chain variable region and/or at least a portion of a light chain variable region may also be referred to as an "arm" or "hemimer” or "half antibody.”
• a hemimer comprises a sufficient portion of a heavy chain variable region to allow
• a hemimer comprises a knob mutation or a hole mutation, for example, to allow
• a multispecific antibody provided herein may be a bispecific antibody.
• the term "bispecific antibody” is used in the broadest sense and covers a multispecific antibody comprising an antigen-binding domain that is capable of specifically binding to two different epitopes on one biological molecule or is capable of specifically binding to epitopes on two different biological molecules.
• a bispecific antibody may also be referred to herein as having "dual specificity" or as being “dual specific.”
• Bispecific antibodies can be prepared as full length antibodies or antibody fragments.
• biparatopic antibody refers to a bispecific antibody where a first antigen- binding domain and a second antigen-binding domain bind to two different epitopes on the same antigen molecule or it may bind to epitopes on two different antigen molecules.
• the first antigen-binding domain and the second antigen- binding domain of the biparatopic antibody may bind the two epitopes within one and the same antigen molecule (intramolecular binding).
• the first antigen-binding domain and the second antigen-binding domain of the biparatopic antibody may bind to two different epitopes on the same antibody molecule.
• the two different epitopes that a biparatopic antibody binds are epitopes that are not normally bound at the same time by one monospecific antibody, such as e.g. a conventional antibody or one immunoglobulin single variable domain.
• the first antigen-binding domain and the second antigen- binding domain of the biparatopic antibody may bind epitopes located within two distinct antigen molecules.
• Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein and Cuello, Nature 305: 537 (1983)), WO 93/08829, and Traunecker et al, EMBO J. 10: 3655 (1991)), and "knob-in-hole” engineering (see, e.g., U.S. Patent No. 5,731,168), WO2009/089004, US2009/0182127, US2011/0287009, Marvin and Zhu, Acta Pharmacol. Sin. (2005) 26(6):649-658, and Kontermann (2005) Acta Pharmacol. Sin., 26: 1-9).
• KnH knock-into-hole
• a protuberance for example, KnHs have been introduced in the Fc:Fc binding interfaces, CL:CH1 interfaces or VH/VL interfaces of antibodies (see, e.g., US 2011/0287009, US2007/0178552, WO 96/027011, WO 98/050431, and Zhu et al, 1997, Protein Science 6:781-788).
• KnHs drive the pairing of two different heavy chains together during the manufacture of multispecific antibodies.
• multispecific antibodies having KnH in their Fc regions can further comprise single variable domains linked to each Fc region, or further comprise different heavy chain variable domains that pair with similar or different light chain variable domains.
• KnH technology can be also be used to pair two different receptor extracellular domains together or any other polypeptide sequences that comprises different target recognition sequences (e.g., including affibodies, peptibodies and other Fc fusions).
• knock mutation refers to a mutation that introduces a protuberance (knob) into a polypeptide at an interface in which the polypeptide interacts with another polypeptide.
• the other polypeptide has a hole mutation.
• a “protuberance” refers to at least one amino acid side chain which proj ects from the interface of a first polypeptide and is therefore positionable in a compensatory cavity in the adj acent interface (i.e. the interface of a second polypeptide) so as to stabilize the heteromultimer, and thereby favor heteromultimer formation over homomultimer formation, for example.
• the protuberance may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface). In some embodiments, nucleic acid encoding the interface of the first polypeptide is altered to encode the protuberance.
• nucleic acid encoding at least one "original” amino acid residue in the interface of the first polypeptide is replaced with nucleic acid encoding at least one "import” amino acid residue which has a larger side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue.
• the side chain volumes of the various amino residues are shown, for example, in Table 1 of US2011/0287009. A mutation to introduce a
• protuberance may be referred to as a "knob mutation.”
• import residues for the formation of a protuberance are naturally occurring amino acid residues selected from arginine (R), phenylalanine (F), tyrosine (Y) and tryptophan (W).
• an import residue is tryptophan or tyrosine.
• the original residue for the formation of the protuberance has a small side chain volume, such as alanine, asparagine, aspartic acid, glycine, serine, threonine or valine.
• a “cavity” refers to at least one amino acid side chain which is recessed from the interface of a second polypeptide and therefore accommodates a corresponding protuberance on the adjacent interface of a first polypeptide.
• the cavity may exist in the original interface or may be introduced synthetically (e.g. by altering nucleic acid encoding the interface).
• nucleic acid encoding the interface of the second polypeptide is altered to encode the cavity.
• the nucleic acid encoding at least one "original” amino acid residue in the interface of the second polypeptide is replaced with DNA encoding at least one "import” amino acid residue which has a smaller side chain volume than the original amino acid residue. It will be appreciated that there can be more than one original and corresponding import residue.
• import residues for the formation of a cavity are naturally occurring amino acid residues selected from alanine (A), serine (S), threonine (T) and valine (V).
• an import residue is serine, alanine or threonine.
• the original residue for the formation of the cavity has a large side chain volume, such as tyrosine, arginine, phenylalanine or tryptophan.
• a mutation to introduce a "cavity" may be referred to as a "hole mutation.”
• the protuberance is "positionable" in the cavity which means that the spatial location of the protuberance and cavity on the interface of a first polypeptide and second polypeptide respectively and the sizes of the protuberance and cavity are such that the protuberance can be located in the cavity without significantly perturbing the normal association of the first and second polypeptides at the interface. Since protuberances such as Tyr, Phe and Trp do not typically extend perpendicularly from the axis of the interface and have preferred
• the alignment of a protuberance with a corresponding cavity may, in some instances, rely on modeling the protuberance/cavity pair based upon a three-dimensional structure such as that obtained by X-ray crystallography or nuclear magnetic resonance (NMR). This can be achieved using widely accepted techniques in the art.
• a knob mutation in an IgGl constant region is T366W.
• a hole mutation in an IgGl constant region comprises one or more mutations selected from T366S, L368A and Y407V.
• a hole mutation in an IgGl constant region comprises T366S, L368A and Y407V.
• a knob mutation in an IgG4 constant region is T366W.
• a hole mutation in an IgG4 constant region comprises one or more mutations selected from T366S, L368A, and Y407V.
• a hole mutation in an IgG4 constant region comprises T366S, L368A, and Y407V.
• Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004A1); cross-linking two or more antibodies or fragments (see, e.g., US 4676980, and Brennan et al, Science, 229: 81 (1985)); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny et al, J. Immunol , 148(5): 1547-1553 (1992)); using "diabody” technology for making bispecific antibody fragments (Hollinger et al, Proc. Natl. Acad. Sci.
• one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant.
• the Fc region variant may comprise a human Fc region sequence (e.g. , a human IgGl, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.
• the invention contemplates an antibody variant that possesses some but not all effector functions, which make it a desirable candidate for applications in which the half life of the antibody in vivo is important yet certain effector functions (such as complement and ADCC) are unnecessary or deleterious.
• In vitro and/or in vivo cytotoxicity assays can be conducted to confirm the reduction/depletion of CDC and/or ADCC activities.
• Fc receptor (FcR) binding assays can be conducted to ensure that the antibody lacks FcyR binding (hence likely lacking ADCC activity), but retains FcRn binding ability.
• NK cells express Fc(RIII only, whereas monocytes express Fc(RI, Fc(RII and Fc(RIII.
• FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991).
• Non- limiting examples of in vitro assays to assess ADCC activity of a molecule of interest is described in US 5500362 (see, e.g. Hellstrom, I. et al. Proc. Nat ⁇ Acad. Sci. USA 83:7059- 7063 (1986)) and Hellstrom, I et al, Proc. Nat 7 Acad. Sci. USA 82: 1499-1502 (1985);
• non-radioactive assays methods may be employed (see, for example, ACTITM non-radioactive cytotoxicity assay for flow cytometry (CellTechnology, Inc. Mountain View, CA; and CytoTox 96 ® non-radioactive cytotoxicity assay (Promega, Madison, WI).
• Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and Natural Killer (NK) cells.
• PBMC peripheral blood mononuclear cells
• NK Natural Killer
• ADCC activity of the molecule of interest may be assessed in vivo, e.g.
• Clq binding assays may also be carried out to confirm that the antibody is unable to bind Clq and hence lacks CDC activity. See, e.g., Clq and C3c binding ELISA in WO 2006/029879 and WO 2005/100402.
• a CDC assay may be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202: 163 (1996); Cragg, M.S. et al., Blood 101 : 1045-1052 (2003); and Cragg, M.S.
• FcRn binding and in vivo clearance/half life determinations can also be performed using methods known in the art (Petkova, S.B. et al, Int 'l. Immunol. 18(12): 1759-1769 (2006)).
• Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056).
• Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitution of residues 265 and 297 to alanine (US 7332581).
• Pro329 of a wild-type human Fc region is substituted with glycine or arginine or an amino acid residue large enough to destroy the proline sandwich within the Fc/Fcy receptor interface, that is formed between the proline329 of the Fc and tryptophan residues Trp 87 and Trp 110 of FcgRIII (Sondermann et al : Nature 406, 267-273 (20 July 2000)).
• At least one further amino acid substitution in the Fc variant is S228P, E233P, L234A, L235A, L235E, N297A, N297D, or P331 S and still in another embodiment said at least one further amino acid substitution is L234A and L235A of the human IgGl Fc region or S228P and L235E of the human IgG4 Fc region (US 8969526 which is incorporated by reference in its entirety).
• a polypeptide comprises the Fc variant of a wild-type human IgG Fc region wherein the polypeptide has Pro329 of the human IgG Fc region substituted with glycine and wherein the Fc variant comprises at least two further amino acid
• the polypeptide comprising the P329G, L234A and L235A substitutions exhibit a reduced affinity to the human FcyRIIIA and FcyRIIA, for down-modulation of ADCC to at least 20% of the ADCC induced by the polypeptide comprising the wild type human IgG Fc region, and/or for down-modulation of ADCP (US 8969526 which is incorporated by reference in its entirety).
• polypeptide comprising an Fc variant of a wild type human Fc polypeptide comprises a triple mutation: an amino acid substitution at position Pro329, a L234A and a L235A mutation (P329 / LALA) (U.S. Patent No. 8,969,526 which is incorporated by reference in its entirety).
• the polypeptide comprises the following amino acid substitutions: P329G, L234A, and L235A.
• an antibody variant comprises an Fc region with one or more amino acid substitutions which improve ADCC, e.g. , substitutions at positions 298, 333, and/or 334 of the Fc region (EU numbering of residues).
• alterations are made in the Fc region that result in altered (i.e., either improved or diminished) Clq binding and/or Complement Dependent Cytotoxicity (CDC), e.g. , as described in US 6194551, WO 1999/51642, and Idusogie et al, J. Immunol. 164: 4178-4184 (2000).
• CDC Complement Dependent Cytotoxicity
• Antibodies with increased half-lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus are described in US2005/0014934A1 (Hinton et al.). Those antibodies comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn.
• Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g. , substitution of Fc region residue 434 (US 7371826).
• cysteine engineered antibodies e.g. , "THIOMABTM antibody”
• one or more residues of an antibody are substituted with cysteine residues.
• the substituted residues occur at accessible sites of the antibody.
• reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to the drug moiety to create an immunoconjugate, as described further herein.
• any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; K149 (Kabat numbering) of the light chain; Al 18 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region.
• Cysteine engineered antibodies may be generated as described, e.g. , in US 7521541 ; Shen, B. et al (2012) Nat. Biotechnol. 30(2): 184-189; Sukumaran et al (2015) Pharm Res 32: 1884-1893.
• Antibody-drug conjugates may be formed by conjugating one or more antibody cysteine thiol groups to one or more linker moieties bound to a drug thereby forming an antibody-linker-drug complex.
• Cysteine thiols are reactive nucleophiles at neutral pH, unlike most amines which are protonated and less nucleophilic near pH 7. Since free thiol (RSH, sulfhydryl) groups are relatively reactive, proteins with cysteine residues often exist in their oxidized form as disulfide-linked oligomers or have internally bridged disulfide groups.
• Antibody cysteine thiol groups are generally more reactive, i.e.
• the protein oxi datively forms an intramolecular disulfide bond between the newly engineered Cys and an existing Cys residue, both Cys groups are unavailable for active site participation and interactions.
• the protein may be rendered inactive or non-specific, by misfolding or loss of tertiary structure (Zhang et al. (2002) Anal. Biochem. 311 : 1-9).
• a THIOMABTM antibody comprises one of the heavy or light chain cysteine substitutions listed in Table 1 below.
• a THIOMABTM antibody comprises one of the heavy chain cysteine substitutions listed in Table 2.
• a THIOMABTM antibody comprises one of the light chain cysteine substitutions listed in Table 3
• a THIOMABTM antibody comprises one of the heavy or light chain cysteine substitutions listed in Table 4.
• Cysteine engineered antibodies which may be useful in the antibody-drug conjugates of the invention in the treatment of cancer include, but are not limited to, antibodies against cell surface receptors and tumor-associated antigens (TAA). Tumor-associated antigens are known in the art, and can be prepared for use in generating antibodies using methods and information which are well known in the art. In attempts to discover effective cellular targets for cancer diagnosis and therapy, researchers have sought to identify transmembrane or otherwise tumor-associated polypeptides that are specifically expressed on the surface of one or more particular type(s) of cancer cell as compared to on one or more normal noncancerous cell(s).
• TAA tumor-associated antigens
• tumor-associated polypeptides are more abundantly expressed on the surface of the cancer cells as compared to on the surface of the non-cancerous cells.
• the identification of such tumor-associated cell surface antigen polypeptides has given rise to the ability to specifically target cancer cells for destruction via antibody-based therapies.
• TAA tumor-associated antigens
• TAA (1)- (53) listed herein.
• information relating to these antigens, all of which are known in the art, is listed herein and includes names, alternative names, Genbank accession numbers and primary reference(s), following nucleic acid and protein sequence identification conventions of the National Center for Biotechnology Information (NCBI).
• NCBI National Center for Biotechnology Information
• Nucleic acid and protein sequences corresponding to TAA (l)-(53) are available in public databases such as GenBank.
• Tumor-associated antigens targeted by antibodies include all amino acid sequence variants and isoforms possessing at least about 70%, 80%, 85%, 90%, or 95% sequence identity relative to the sequences identified in the cited references, or which exhibit substantially the same biological properties or characteristics as a TAA having a sequence found in the cited references.
• a TAA having a variant sequence generally is able to bind specifically to an antibody that binds specifically to the TAA with the corresponding sequence listed.
• BMPR1B bone morphogenetic protein receptor-type IB, Genbank accession no. NM_001203
• Dijke P., et al. Science 264 (5155): 101-104 (1994)
• NP_001194 bone morphogenetic protein receptor, type IB /pid NP_001194.1 - Cross-references: MIM:603248; NP_001194.1; AY065994.
• WO200289747 (Example 5; Page 618-619); WO2003022995 (Example 9; Fig 13A, Example 53; Page 173, Example 2; Fig 2A); NP_036581 six transmembrane epithelial antigen of the prostate Cross-references: MIM: 604415; NP_036581.1; NM_012449_1. (4) 0772P (CA125, MUC16, Genbank accession no. AF361486) J. Biol. Chem. 276
• MPF MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin
• WO2003101283 (Claim 14); (WO2002102235 (Claim 13; Page 287-288); WO2002101075 (Claim 4; Page 308-309); WO200271928 (Page 320-321); WO9410312 (Page 52-57); Cross- references: MIM:601051 ; NP_005814.2; NM_005823_1.
• Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b,Genbank accession no. NM_006424) J. Biol. Chem. 277 (22): 19665-19672 (2002), Genomics 62 (2):281-284 (1999), Feild, J.A., et al. (1999) Biochem. Biophys. Res. Commun. 258 (3):578-
• Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b
• Hlog Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B, Genbank accession no.
• WO2003003984 (Claim 1); WO200206339 (Claim 1 ; Page 50); WO200188133 (Claim 1; Page 41-43, 48-58); WO2003054152 (Claim 20); WO2003101400 (Claim 11); Accession:
• PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene, Genbank accession no. AY358628); Ross et al. (2002) Cancer Res. 62:2546-2553; US2003129192 (Claim 2); US2004044180 (Claim 12);
• WO2003025148 (Claim 20); Cross-references: GF37182378; AAQ88991.1; AY358628_1.
• ETBR Endothelin type B receptor, Genbank accession no. AY275463
• WO2004048938 (Example 2); WO2004040000 (Claim 151); WO2003087768 (Claim 1); WO2003016475 (Claim 1); WO2003016475 (Claim 1); WO200261087 (Fig 1);
• WO2003016494 (Fig 6); WO2003025138 (Claim 12; Page 144); WO200198351 (Claim 1; Page 124-125); EP522868 (Claim 8; Fig 2); WO200177172 (Claim 1; Page 297-299);
• MSG783 (RNF124, hypothetical protein FLJ20315, Genbank accession no. NM_017763); WO2003104275 (Claim 1); WO2004046342 (Example 2); WO2003042661
• STEAP2 (HGNC 8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein, Genbank accession no. AF455138) Lab. Invest. 82 (11): 1573-1582 (2002)); WO2003087306; US2003064397 (Claim 1; Fig 1); WO200272596 (Claim 13; Page 54-55); WO200172962 (Claim 1; Fig 4B); WO2003104270 (Claim 11); WO2003104270 (Claim 16); US2004005598 (Claim 22);
• WO2003042661 (Claim 12); US2003060612 (Claim 12; Fig 10); WO200226822 (Claim 23; Fig 2); WO200216429 (Claim 12; Fig 10); Cross-references: GF22655488; AAN04080.1; AF455138_1.
• TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4, Genbank accession no. NM_017636) Xu, X.Z., et al. Proc. Natl. Acad. Sci. U.S.A. 98 (19): 10692-10697 (2001), Cell 109 (3):397-407 (2002), J. Biol. Chem.
• CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor, Genbank accession no. NP_003203 or NM_003212) Ciccodicola, A, et al. EMBO J. 8 (7): 1987-1991 (1989), Am. J. Hum. Genet.
• CD21 (CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs.73792 Genbank accession no. M26004) Fujisaku et al. (1989) J. Biol. Chem. 264 (4):2118-2125); Weis J.J., et al. J. Exp. Med. 167, 1047-1066, 1988; Moore M., et al.
• CD79b (CD79B, CD79P, IGb (immunoglobulin-associated beta), B29, Genbank accession no. NM_000626 or 11038674) Proc. Natl. Acad. Sci. U.S.A. (2003) 100 (7):4126- 4131, Blood (2002) 100 (9):3068-3076, Muller et al. (1992) Eur. J. Immunol.
• FcRH2 (IFGP4, IRTA4, SPAP1A (SH2 domain containing phosphatase anchor protein la), SPAP1B, SPAP1C, Genbank accession no. NM_030764, AY358130) Genome Res. 13 (10):2265-2270 (2003), Immunogenetics 54 (2):87-95 (2002), Blood 99 (8):2662- 2669 (2002), Proc. Natl. Acad. Sci. U.S.A. 98 (17):9772-9777 (2001), Xu, M.J., et al. (2001) Biochem. Biophys. Res. Commun. 280 (3):768-775; WO2004016225 (Claim 2);
• WO2003077836 WO200138490 (Claim 5; Fig 18D-1-18D-2); WO2003097803 (Claim 12); WO2003089624 (Claim 25); Cross-references: MIM:606509; NP_110391.2; NM_030764_1.
• HER2 ErbB2, Genbank accession no. Ml 1730
• Yamamoto T. et al. Nature 319, 230-234, 1986
• Semba K. et al. Proc. Natl. Acad. Sci. U.S.A. 82, 6497-6501, 1985
• Swiercz J.M. et al. J. Cell Biol. 165, 869-880, 2004
• Cho H.-S. et al.
• WO2003055439 (Claim 29; Fig 1A-B); WO2003025228 (Claim 37; Fig 5C); WO200222636 (Example 13; Page 95-107); WO200212341 (Claim 68; Fig 7); WO200213847 (Page 71-74); WO200214503 (Page 114-117); WO200153463 (Claim 2; Page 41-46); WO200141787 (Page 15); WO200044899 (Claim 52; Fig 7); WO200020579 (Claim 3; Fig 2); US5869445 (Claim 3; Col 31-38); WO9630514 (Claim 2; Page 56-61); EP1439393 (Claim 7);
• WO2004043361 (Claim 7); WO2004022709; WO200100244 (Example 3; Fig 4); Accession: P04626; EMBL; Ml 1767; AAA35808.1. EMBL; Ml 1761; AAA35808.1.
• NCA NCA (CEACAM6, Genbank accession no. Ml 8728); Barnett T., et al. Genomics 3, 59-66, 1988; Tawaragi Y., et al. Biochem. Biophys. Res. Commun. 150, 89-96, 1988; Strausberg R.L., et al. Proc. Natl. Acad. Sci. U.S.A.
• WO200260317 (Claim 2); Accession: P40199; Q14920; EMBL; M29541; AAA59915.1. EMBL; Ml 8728.
• IL20Ra (IL20Ra, ZCYTOR7, Genbank accession no. AF184971); Clark H.F., et al. Genome Res. 13, 2265-2270, 2003; Mungall A.J., et al. Nature 425, 805-811, 2003;
• EphB2R (DRT, ERK, Hek5, EPHT3, Tyro5, Genbank accession no.
• PSCA Prostate stem cell antigen precursor, Genbank accession no. AJ297436
• Reiter R.E. et al. Proc. Natl. Acad. Sci. U.S.A. 95, 1735-1740, 1998; Gu Z., et al. Oncogene 19, 1288-1296, 2000; Biochem. Biophys. Res. Commun. (2000) 275(3):783-788;
• BAFF-R B cell -activating factor receptor, BLyS receptor 3, BR3, Genbank accession No. AF116456
• BAFF receptor /pid NP_443177.1 - Homo sapiens Thompson, J.S., et al. Science 293 (5537), 2108-2111 (2001); WO2004058309; WO2004011611 ;
• WO2003045422 (Example; Page 32-33); WO2003014294 (Claim 35; Fig 6B);
• WO2003035846 (Claim 70; Page 615-616); WO200294852 (Col 136-137); WO200238766
• CD22 B-cell receptor CD22-B isoform, BL-CAM, Lyb-8, Lyb8, SIGLEC-2
• CD79a (CD79A, CD79a, immunoglobulin-associated alpha, a B cell-specific protein that covalently interacts with Ig beta (CD79B) and forms a complex on the surface with Ig M molecules, transduces a signal involved in B-cell differentiation), pi: 4.84, MW: 25028 TM: 2 [P] Gene Chromosome: 19ql3.2, Genbank accession No. NP_001774.10) WO2003088808, US20030228319; WO2003062401 (claim 9); US2002150573 (claim 4, pages 13-14); W09958658 (claim 13, Fig 16); WO9207574 (Fig 1); US5644033; Ha et al. (1992) J. Immunol.
• CXCR5 Burkitt's lymphoma receptor 1, a G protein-coupled receptor that is activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, plays a role in HIV -2 infection and perhaps development of AIDS, lymphoma, myeloma, and leukemia); 372 aa, pi: 8.54 MW: 41959 TM: 7 [P] Gene Chromosome: l lq23.3, Genbank accession No. NP_001707.1) WO 2004040000; WO2004/015426; US2003105292 (Example 2); US6555339 (Example 2); WO 2002/61087 (Fig 1);
• WO200157188 (Claim 20, page 269); WO200172830 (pages 12-13); WO 2000/22129 (Example 1, pages 152-153, Example 2, pages 254-256); WO 199928468 (claim 1, page 38); US 5440021 (Example 2, col 49-52); W09428931 (pages 56-58); WO 1992/17497 (claim 7, Fig 5); Dobner et al. (1992) Eur. J. Immunol. 22:2795-2799; Barella et al. (1995) Biochem. J. 309:773-779.
• HLA-DOB Beta subunit of MHC class II molecule (la antigen) that binds peptides and presents them to CD4+ T lymphocytes); 273 aa, pi: 6.56 MW: 30820 TM: 1 [P] Gene Chromosome: 6p21.3, Genbank accession No. NP_002111.1) Tonnelle et al. (1985) EMBO J. 4(l l):2839-2847; Jonsson et al. (1989) Immunogenetics 29(6):411-413; Beck et al. (1992) J. Mol. Biol. 228:433-441; Strausberg et al. (2002) Proc. Natl. Acad. Sci USA
• P2X5 Purinergic receptor P2X ligand-gated ion channel 5, an ion channel gated by extracellular ATP, may be involved in synaptic transmission and neurogenesis, deficiency may contribute to the pathophysiology of idiopathic detrusor instability
• 422 aa pi: 7.63, MW: 47206 TM: 1
• Gene Chromosome 17pl3.3, Genbank accession No. NP_002552.2) Le et al. (1997) FEBS Lett. 418(1-2): 195-199; WO2004047749; WO2003072035 (claim 10); Touchman et al. (2000) Genome Res. 10: 165-173; WO200222660 (claim 20);
• CD72 B-cell differentiation antigen CD72, Lyb-2
• pi 8.66
• MW 40225 TM: 1
• Gene Chromosome 9pl3.3, Genbank accession No. NP_001773.1
• LY64 Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family, regulates B-cell activation and apoptosis, loss of function is associated with increased disease activity in patients with systemic lupus erythematosis); 661 aa, pi: 6.20, MW: 74147 TM: 1 [P] Gene Chromosome: 5ql2, Genbank accession No.
• FcRHl Fc receptor-like protein 1, a putative receptor for the immunoglobulin Fc domain that contains C2 type Ig-like and ITAM domains, may have a role in B-lymphocyte differentiation); 429 aa, pi: 5.28, MW: 46925 TM: 1 [P] Gene Chromosome: Iq21-lq22,
• IRTA2 Immunoglobulin superfamily receptor translocation associated 2, a putative immunoreceptor with possible roles in B cell development and lymphomagenesis; deregulation of the gene by translocation occurs in some B cell malignancies
• TENB2 (TMEFF2, tomoregulin, TPEF, HPP1, TR, putative transmembrane proteoglycan, related to the EGF/heregulin family of growth factors and follistatin); 374 aa, NCBI Accession: AAD55776, AAF91397, AAG49451, NCBI RefSeq: NP_057276; NCBI
• PMEL17 (silver homolog; SILV; D12S53E; PMEL17; SI; SIL); ME20; gplOO) BC001414; BT007202; M32295; M77348; NM_006928; McGlinchey, R.P. et al. (2009) Proc. Natl. Acad. Sci. U.S.A. 106 (33), 13731-13736; Kummer, M.P. et al. (2009) J. Biol. Chem. 284 (4), 2296-2306.
• TMEFF1 transmembrane protein with EGF-like and two follistaiin-like domains 1; Tomoregulin-1); H7365; C9orf2; C90RF2; U19878; X83961; NM_080655; NM_003692; Harms, P.W. (2003) Genes Dev. 17 (21), 2624-2629; Gery, S. et al. (2003) Oncogene 22 (18):2723-2727.
• GDNF-Ral GDNF family receptor alpha 1; GFRA1; GDNFR; GDNFRA; RETL1; TRNR1; RET1L; GDNFR-alphal ; GFR-ALPHA-1); U95847; BC014962;
• Ly6E lymphocyte antigen 6 complex, locus E; Ly67,RIG-E,SCA-2,TSA-l
• NP_002337.1 NP_002346.2
• de Nooij-van Dalen A G. et al. (2003) Int. J. Cancer 103 (6), 768-774
• TMEM46 shisa homolog 2 (Xenopus laevis); SHISA2
• NP_001007539.1 M 001007538.1
• Ly6G6D lymphocyte antigen 6 complex, locus G6D; Ly6-D, MEGT1;
• LGR5 (]eucme ⁇ rich repeat-containing G protein-coupled receptor 5; GPR49, GPR67); NP_003658.1; NM_003667.2; Salanti, G. et al. (2009) Am. J. Epidemiol. 170 (5):537-545; Yamamoto, Y. et al. (2003) Hepatology 37 (3):528-533.
• RET ret proto-oncogene
• MEN2A proto-oncogene
• HSCR1 HSCR1
• MEN2B MTC1
• PTC CDHF12
• Hs.168114 RET51
• RET-ELEl NP_066124.1
• NM_020975.4 Tsukamoto, H. et al. (2009)
• LY6K lymphocyte antigen 6 complex, locus K; LY6K; HSJ001348; FLJ35226; NP_059997.3; NM_017527.3; Ishikawa, N. et al. (2007) Cancer Res. 67 (24): 11601-11611; de Nooij-van Dalen, A G. et al. (2003) Int. J. Cancer 103 (6):768-774.
• GPR19 G protein-coupled receptor 19; Mm.4787); NP_006134.1 ;
• GPR54 KISS1 receptor; KISSIR; GPR54; HOT7T175; AXOR12;
• ASPHD1 aspartate heta-hydroxylase domain containing 1 ; LOC253982
• TMEM118 ring finger protein, transmembrane 2; RNFT2; FLJ14627
• GPR172A G protein-coupled receptor 172 A; GPCR41; FLJ11856;
• CD33 a member of the sialic acid binding, immunoglobulin-like lectin family, is a 67-kDa glycosylated transmembrane protein. CD33is expressed on most myeloid and monocytic leukemia cells in addition to committed myelomonocytic and erythroid progenitor cells. It is not seen on the earliest pluripotent stem cells, mature granulocytes, lymphoid cells, or nonhematopoietic cells (Sabbath et al, (1985) J. Clin. Invest. 75:756-56; Andrews et al, (1986) Blood 68: 1030-5). CD33 contains two tyrosine residues on its cytoplasmic tail, each of which is followed by hydrophobic residues similar to the immunoreceptor tyrosine-based inhibitory motif (ITIM) seen in many inhibitory receptors.
• ITIM immunoreceptor tyrosine-based inhibitory motif
• CLL-1 (CLEC12A, MICL, and DCAL2)
• CTL/CTLD C-type lectin-like domain
• CLL-1 has been shown to be a type II transmembrane receptor comprising a single C-type lectin-like domain (which is not predicted to bind either calcium or sugar), a stalk region, a
• transmembrane domain and a short cytoplasmic tail containing an ITIM motif.
• an antibody provided herein may be further modified to contain additional nonproteinaceous moieties that are known in the art and readily available.
• the moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers.
• water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3- dioxolane, poly-l,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propropylene glycol homopolymers, polypropylene oxide/ethylene oxide copolymers, polyoxyethylated polyols (e.g.
• Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water.
• the polymer may be of any molecular weight, and may be branched or unbranched.
• the number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.
• conjugates of an antibody and nonproteinaceous moiety that may be selectively heated by exposure to radiation are provided.
• the nonproteinaceous moiety is a carbon nanotube (Kam et al, Proc. Natl. Acad. Sci. USA 102: 11600-11605 (2005)).
• the radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the nonproteinaceous moiety to a temperature at which cells proximal to the antibody -nonproteinaceous moiety are killed.
• Antibodies may be produced using recombinant methods and compositions, e.g. , as described in US 4816567.
• Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g. , the light and/or heavy chains of the antibody).
• one or more vectors e.g. , expression vectors
• a host cell comprising such nucleic acid is provided.
• a host cell comprises (e.g.
• the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell or lymphoid cell (e.g. , Y0, NSO, Sp20 cell).
• CHO Chinese Hamster Ovary
• lymphoid cell e.g. , Y0, NSO, Sp20 cell
• nucleic acid encoding an antibody is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell.
• nucleic acid may be readily isolated and sequenced using conventional procedures (e.g. , by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).
• Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein.
• antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed.
• For expression of antibody fragments and polypeptides in bacteria see, e.g., US 5648237, US 5789199, and US 5840523. (See also Charlton, Methods in Molecular Biology, Vol. 248 (B.K.C. Lo, ed., Humana Press, Totowa, NJ, 2003), pp. 245-254, describing expression of antibody fragments in E. coli.)
• the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.
• eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including fungi and yeast strains whose glycosylation pathways have been "humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, Nat. Biotech. 22: 1409-1414 (2004), and Li et al, Nat. Biotech. 24:210-215 (2006).
• Suitable host cells for the expression of glycosylated antibody are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of Spodoptera frugiperda cells.
• Plant cell cultures can also be utilized as hosts. See, e.g. , US 5959177; US 6040498; US 6420548; US 7125978; US 6417429 (describing PLANTIBODIESTM technology for producing antibodies in transgenic plants).
• Vertebrate cells may also be used as hosts.
• mammalian cell lines that are adapted to grow in suspension may be useful.
• Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham et al, J. Gen Virol. 36:59 (1977)); baby hamster kidney cells (BHK); mouse Sertoli cells (TM4 cells as described, e.g., in Mather, Biol. Reprod.
• monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo rat liver cells (BRL 3 A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g. , in Mather et al, Annals N.Y. Acad. Sci. 383 :44-68 (1982); MRC 5 cells; and FS4 cells.
• Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR "
• CHO cells Urlaub et al, Proc. Natl. Acad. Sci. USA 77:4216 (1980)); and myeloma cell lines such as Y0, NS0 and Sp2/0.
• myeloma cell lines such as Y0, NS0 and Sp2/0.
• a “Linker” (L) is a bifunctional or multifunctional moiety that can be used to link one or more silvestrol drug moieties to an antibody (Ab) to form an antibody-drug conjugate (ADC) of Formulas Ila and lib.
• antibody-drug conjugates (ADC) can be prepared using a Linker having reactive functionalities for covalently attaching to the drug and to the antibody.
• a cysteine thiol of an antibody (Ab) can form a bond with a reactive functional group of a linker or a drug-linker intermediate to make an ADC.
• a linker has a functionality that is capable of reacting with a free cysteine present on an antibody to form a covalent bond.
• reactive functionalities include maleimide, haloacetamides, a-haloacetyl, pyridyl disulfide, activated esters such as succinimide esters, N-hydroxysuccinimide, 4-nitrophenyl esters, pentafluorophenyl esters, tetrafluorophenyl esters, anhydrides, acid chlorides, sulfonyl chlorides, isocyanates, and isothiocyanates. See, e.g. , the conjugation method at page 766 of Klussman, et al (2004), Bioconjugate Chemistry 15(4): 765-773, and the Examples herein.
• a linker has a functionality that is capable of reacting with an electrophilic group present on an antibody.
• electrophilic groups include, but are not limited to, aldehyde and ketone carbonyl groups.
• a heteroatom of the reactive functionality of the linker can react with an electrophilic group on an antibody and form a covalent bond to an antibody unit.
• Nonlimiting exemplary reactive functionalities include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide.
• a linker may comprise one or more linker components, including but not limited to, a stretcher unit, a peptidomimetic unit, a peptide unit, and a spacer unit.
• exemplary linker components include 6-maleimidocaproyl ("MC"), maleimidopropanoyl ("MP”), valine- citrulline (“val-cit” or “vc”), alanine-phenylalanine ("ala-phe”), phenylalanine-lysine (phe- lys), p-aminobenzyloxycarbonyl (a "PAB”), N-Succinimidyl 4-(2-pyridylthio) pentanoate (“SPP”), and 4-(N-maleimidomethyl) cyclohexane-1 carboxylate (“MCC”).
• MC 6-maleimidocaproyl
• MP maleimidopropanoyl
• val-cit valine- citrulline
• a linker may be a "cleavable linker," facilitating release of a drug.
• Nonlimiting exemplary cleavable linkers include acid-labile linkers (e.g. , comprising hydrazone), protease-sensitive (e.g., peptidase-sensitive) linkers, photolabile linkers, or disulfide- containing linkers (Chari et al, Cancer Research 52: 127-131 (1992); US 5208020).
• linkers are described in US 7498298, which is expressly incorporated herein by reference.
• Silvestrol (CAS Reg. No. 697235-38-4), named as methyl (lR,2R,3S,3aR,8bS)-6- (((2S,3R,6R)-6-((R)-l,2-dihydroxyethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8- methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran- 2-carboxylate (compound 16, Example la), is a rocaglate derivative isolated from Aglaia foveolata (Pan, L., et al (2014) Nat.
• Silvestrol and analogs are potent and selective protein synthesis inhibitors and have been studied for their anti-hyperproliferative properties (Liu, T. et al (2012) Journal of Medicinal Chemistry, 55(20): 8859-8878; WO 2015/085221 ; WO 2013016658; WO 2004041812; US 8137509; US 8404088; WO 2006007634; US 7816544).
• Silvestrol has the structure:
• Silvestrol-linker intermediates of Formula II are prepared according to the procedure of the Examples.
• R a is a group selected from CH 3 0, CN, N0 2 , and CI;
• R 1 is selected from -OCH 3 and L-X;
• R 2 is selected from -CH(OH)CH 2 OH, and L-X
• L is a linker
• X comprises a reactive functional group selected from maleimide, thiol, amino, bromide, bromoacetamido, iodoacetamido, p-toluenesulfonate, iodide, hydroxyl, carboxyl, pyridyl disulfide, and N-hydroxysuccinimide.
• L-X is selected from -CH 2 CH 2 -X, -CH 2 CR 2 -X, - C(0)NRCH 2 -X, -CH 2 0-X, -CH 2 N(R)-X, -N(R)-X, -N(R)(Ci-Ci 2 alkylene)- X, -N(R)(C 2 -C 8 alkenylene)-X, -N(R)(C 2 -C 8 alkynylene)-X, and -N(R)(CH 2 CH 2 0) n -X ; n is 1 to 6;
• R is independently selected from H, Cr-C 12 alkyl, and C6-C 2 o aryl; or two R form a C3-C7 carbocyclic ring;
• alkylene, alkenylene, alkynylene, alkyl, and aryl are optionally substituted with one or more groups selected from F, CI, Br, N(CH 3 ) 2 , N0 2 , and OCH 3 .
• alkylene is selected from -CH 2 CH 2 -, -CH 2 CH 2 CH 2 - -CH(CH 3 )CH 2 - and -C(CH 3 ) 2 CH 2 - .
• X is selected from:
• R 3 is N0 2 , CI, F, CN or Br, and q is 0, 1, or 2.
• R 1 is -OCH 3 and R 2 is L-X.
• R 1 is L-X and R 2 is -CH(OH)CH 2 OH.
• L is a protease-cleavable, non-peptide linker having the formula:
• Str is a stretcher unit covalently attached to X; PM is a peptidomimetic unit, and Y is a spacer unit covalently attached to the silvestrol drug moiety.
• Peptidomimetic linkers are described in WO 2015/095227, WO 2015/095124 or WO 2015/095223, which are hereby incorporated by reference in their entirety.
• Str is (CH 2 )s.
• PM has the formula: where R 7 and R 8 together form a C3-C7 cycloalkyl ring, and
• AA is an amino acid side chain selected from H, -CH 3 , -CH 2 (C 6 H 5 ),
• R 7 and R 8 together form cyclobutyl.
• Y comprises para-aminobenzyl or para- aminobenzyloxy carbonyl .
• L is a peptide linker having the formula:
• Str is a stretcher unit covalently attached to the antibody
• Pep is a peptide of two to twelve amino acid residues
• Y is a spacer unit covalently attached to the silvestrol drug moiety.
• Str is (CH 2 )s.
• Str include the following wherein the wavy line indicates sites of covalent attachment to the antibody, drug, or additional linker components:
• Pep comprises two amino acid residues independently selected from glycine, alanine, phenylalanine, lysine, arginine, valine, and citrulline.
• the silvestrol-linker intermediate compound is selected from the compounds of Table 5.
• Silvestrol-linker intermediate compounds may be purified and isolated according to conventional methods and Examples 1 -3. Purification and isolation methods are known in the art and include precipitation, crystallization, filtration, centrifugation, ultrafiltration, and various chromatographic techniques. Chromatography can involve any number of methods including, e.g. : reverse-phase and normal phase; size exclusion; ion exchange; high, medium and low pressure liquid chromatography methods and apparatus; small scale analytical; simulated moving bed (SMB) and preparative thin or thick layer chromatography, as well as techniques of small scale thin layer and flash chromatography. In some such aspects, the completed reaction mixture may be evaporated to dryness followed by re-dissolution in a polar aprotic solvent.
• the solution may be filtered and then precipitated by combining the solution with a nonpolar antisolvent such as, for instance, hexane or cyclohexane.
• a nonpolar antisolvent such as, for instance, hexane or cyclohexane.
• the precipitate may then be collected by filtration, optionally washed, and then dried.
• the invention provides antibody-drug conjugates having an antibody covalently attached through a linker to a silvestrol drug moiety, selected from Formulas la and Ib :
• R a is a group selected from CH 3 0, CN, N0 2 , and CI;
• L is a linker
• p is an integer from 1 to 8; and Ab is an antibody which binds to one or more tumor-associated antigens or cell- surface receptors.
• the antibody binds to one or more tumor-associated antigens or cell-surface receptors is selected from (l)-(53):
• BMPR1B bone morphogenetic protein receptor-type IB
• MPF MPF
• MSLN MSLN
• SMR megakaryocyte potentiating factor
• mesothelin (6)
• Napi2b NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b);
• Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, Semaphorin 5b Hlog, sema domain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B);
• PSCA hlg (2700050C12Rik, C530008O16Rik, RIKEN cDNA 2700050C12
• ETBR Endothelin type B receptor
• STEAP2 (HGNC 8639, IPCA-1, PCANAP1, STAMP1, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, six transmembrane epithelial antigen of prostate 2, six transmembrane prostate protein);
• TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential cation channel, subfamily M, member 4);
• CRIPTO (CR, CRl, CRGF, CRIPTO, TDGFl, teratocarcinoma-derived growth factor);
• CD21 CR2 (Complement receptor 2) or C3DR (C3d/Epstein Barr virus receptor) or Hs 73792);
• CD79b (CD79B, CD79P, IGb (immunoglobulin-associated beta), B29);
• FcRH2 (IFGP4, IRTA4, SPAPIA (SH2 domain containing phosphatase anchor protein la), SPAP1B, SPAP1C);
• BAFF-R B cell -activating factor receptor, BLyS receptor 3, BR3
• CD22 B-cell receptor CD22-B isoform
• CD79a (CD79A, CD79a, immunoglobulin-associated alpha);
• CXCR5 (Burkitt's lymphoma receptor 1);
• HLA-DOB Beta subunit of MHC class II molecule (la antigen)
• P2X5 Purinergic receptor P2X ligand-gated ion channel 5
• CD72 B-cell differentiation antigen CD72, Lyb-2
• LY64 Lymphocyte antigen 64 (RP105), type I membrane protein of the leucine rich repeat (LRR) family
• FcRHl Fc receptor-like protein 1
• FcRH5 (IRTA2, Immunoglobulin superfamily receptor translocation associated
• TENB2 (putative transmembrane proteoglycan);
• PMEL17 (silver homolog; SILV; D12S53E; PMEL17; SI; SIL);
• TMEFFl transmembrane protein with EGF-like and two follistatin-like domains 1; Tomoregulin-1
• GDNF-Ral GDNF family receptor alpha 1; GFRA1; GDNFR; GDNFRA; RETL1; TRNR1; RET1L; GDNFR-alphal ; GFR-ALPHA-1);
• Ly6E lymphocyte antigen 6 complex, locus E; Ly67,RIG-E,SCA-2,TSA-l;
• TMEM46 shisa homolog 2 (Xenopus iaevis); SHISA2;
• Ly6G6D lymphocyte antigen 6 complex, locus G6D; Ly6-D, MEGT1;
• LGR5 leucine-rich repeat-containing G protein-coupled receptor 5; GPR49, GPR67;
• RET ret proto-oncogene; MEN2A; HSCR1; MEN2B; MTC1; PTC; CDHF12; Hs.168114; RET51; RET-ELE1);
• LY6K lymphocyte antigen 6 complex, locus K; LY6K; HSJ001348; FLJ35226;
• GPR19 G protein-coupled receptor 19; Mm.4787
• GPR54 K! SS i receptor; KISS 1R; GPR54; HOT7T175; AX0R12);
• ASPHD1 aspartate beta-hydroxylase domain containing 1 ; LOC253982
• Tyrosinase (TYR; OCAIA; OCA1A; tyrosinase; SHEP3);
• TMEM1 18 ring finger protein, transmembrane 2; RNFT2; FLJ14627;
• GPR172A G protein-coupled receptor 172 A; GPCR41 ; FLJ11856;
• Ab is selected from anti-HER2 4D5, anti-CD22, anti- CD33, anti- Ly6E, anti-Napi3b, anti-HER2 7C2, and anti-CLL-1.
• Ab is a cysteine-engineered antibody.
• the cysteine-engineered antibody is a mutant selected from HC Al 18C, LC K149C, HC A140C, LC V205C, LC S 121C, and HC L177C.
• L is a protease-cleavable, non-peptide linker having the formula:
• Y is a spacer unit covalently attached to the silvestrol drug moiety.
• Str has the formula:
• R 6 is (CH 2 ) 5 .
• PM has the formula:
• R 7 and R 8 together form a C3-C7 cycloalkyl ring
• AA is an amino acid side chain selected from H, -CH 3 , -CH 2 (C 6 H 5 ), -CH2CH2CH2CH2NH2, -CH2CH 2 CH 2 NHC(NH)NH2, -CHCH(CH 3 )CH 3 , and
• Y comprises para-aminobenzyl or para- aminobenzyloxy carbonyl .
• the antibody-drug conjugate compound has the formul
• D is the silvestrol drug moiety.
• the antibody-drug conjugate compound has the formul
• the antibody-drug conjugate compound has the formul
• the antibody-drug conjugate compound has the formula:
• the antibody-drug conjugate compound is selected from the form las:
• L is a peptide linker having the formula:
• Str is a stretcher unit covalently attached to the antibody
• Pep is a peptide of two to twelve amino acid residues
• Y is a spacer unit covalently attached to the silvestrol drug moiety.
• Str has the formula:
• R 6 is (CH 2 ) 5 .
• Pep comprises two to twelve amino acid residues independently selected from glycine, alanine, phenylalanine, lysine, arginine, valine, and citrulline.
• Pep is selected from valine-citrulline, alanine- phenylalanine, and phenylalanine-lysine.
• Y comprises para-aminobenzyl or para- aminobenzyloxy carbonyl .
• the antibody-drug conjugate compound has the formul
• AA 1 and AA 2 are independently selected from an amino acid side chain.
• the amino acid side chain is independently selected from H, -CH 3 , -CH 2 (C 6 H 5 ), -CH 2 CH 2 CH 2 CH 2 NH 2 , -CH 2 CH 2 CH 2 NHC(NH)NH 2 , -CHCH(CH 3 )CH 3 , and -CH 2 CH 2 CH 2 NHC(0)NH 2 .
• the antibody-drug conjugate compound has the formul
• the antibody-drug conjugate compound has the formula:
• the antibody-drug conjugate compound has the formul
• the antibody-drug conjugate compound has the formul
• the antibody-drug conjugate compound has the formula:
• the antibody-drug conjugate compound has the formul
• the antibody-drug conjugate compound has the formula:
• L comprises a disulfide group.
• p is 1 , 2, 3, or 4.
• the antibody-drug conjugate compound comprises a mixture of the antibody-drug conjugate compounds, wherein the average drug loading per antibody in the mixture of antibody-drug conjugate compounds is about 2 to about 5.
• the antibody-drug conjugate compounds of the invention include those with anticancer activity.
• the antibody-drug conjugates of the invention selectively deliver an effective dose of a drug to tumor tissue, whereby greater selectivity (i. e., a lower efficacious dose) may be achieved while increasing the therapeutic index ("therapeutic window").
• Drug loading is represented by p, the number of silvestrol drug moieties per antibody in a molecule of Formula I. Drug loading may range from 1 to about 8 drug moieties (D) per antibody.
• Antibody-drug conjugates of Formula I include mixtures or collections of antibodies conjugated with a range of drug moieties, from 1 to about 8. In some
• the number of drug moieties that can be conjugated to an antibody is limited by the number of free cysteine residues.
• free cysteine residues are introduced into the antibody amino acid sequence by the methods described herein.
• p may be 1 , 2, 3, 4, 5, 6, 7, or 8, and ranges thereof, such as from 1 to 8 or from 2 to 5.
• Exemplary antibody-drug conjugates of Formula I include, but are not limited to, antibodies that have 1 , 2, 3, or 4 engineered cysteine amino acids (Lyon, R. et al. (2012) Methods in Enzym.
• one or more free cysteine residues are already present in an antibody, without the use of engineering, in which case the existing free cysteine residues may be used to conjugate the antibody to a drug.
• an antibody is exposed to reducing conditions prior to conjugation of the antibody in order to generate one or more free cysteine residues.
• the average number of drug moieties per antibody (DAR) in preparations of antibody-drug conjugates from conjugation reactions may be characterized by conventional means such as mass
• the quantitative distribution of antibody-drug conjugates in terms of p may also be determined.
• separation, purification, and characterization of homogeneous antibody-drug conjugates where p is a certain value from antibody-drug conjugates with other drug loadings may be achieved by means such as reverse phase HPLC or electrophoresis.
• p may be limited by the number of attachment sites on the antibody.
• an antibody may have only one or a limited number of cysteine thiol groups, or may have only one or a limited number of sufficiently reactive thiol groups, to which the drug may be attached.
• higher drug loading e.g. p >5
• the average drug loading for an antibody-drug conjugate ranges from 1 to about 8; from about 2 to about 6; or from about 3 to about 5. Indeed, it has been shown that for certain antibody-drug conjugates, the optimal ratio of drug moieties per antibody may be less than 8, and may be between about 2 to about 5 (see, e.g., US 7498298).
• an antibody may contain, for example, cysteine residues that do not react with the drug, as discussed herein. Generally, antibodies do not contain many free and reactive cysteine thiol groups which may be linked to a drug moiety; indeed most native cysteine thiol residues in antibodies exist as disulfide bridges.
• an antibody may be reduced with a reducing agent such as dithiothreitol (DTT) or tricarbonylethylphosphine (TCEP), under partial or total reducing conditions, to generate reactive cysteine thiol groups.
• DTT dithiothreitol
• TCEP tricarbonylethylphosphine
• an antibody is subjected to denaturing conditions to reveal reactive nucleophilic groups such as lysine or cysteine.
• the loading (drug/antibody ratio) of an antibody-drug conjugate may be controlled in different ways, and for example, by: (i) limiting the molar excess of the silvestrol-linker intermediate compound relative to antibody, (ii) limiting the conjugation reaction time or temperature, and (iii) partial or limiting reductive conditions for cysteine thiol modification.
• the resulting product is a mixture of antibody-drug conjugate compounds with a distribution of one or more drug moieties attached to an antibody.
• the average number of drugs per antibody may be calculated from the mixture by a dual ELISA antibody assay, which is specific for antibody and specific for the drug.
• Individual antibody-drug conjugate molecules may be identified in the mixture by mass spectroscopy and separated by HPLC, e.g. hydrophobic interaction chromatography (see, e.g. , McDonagh et al. (2006) Prot. Engr. Design & Selection 19(7):299-307; Hamblett et al. (2004) Clin. Cancer Res.
• a homogeneous antibody-drug conjugate with a single loading value may be isolated from the conjugation mixture by electrophoresis or chromatography .
• the antibody may be a cysteine engineered antibody as described elsewhere herein and/or may be treated with a reducing agent for reactivity in the conjugation reaction.
• the Ab is dissolved in a physiological buffer system known in the art that will not adversely impact the stability or antigen-binding specificity of the antibody.
• phosphate buffered saline is used.
• the silvestrol-linker intermediate compound is dissolved in a solvent system comprising at least one polar aprotic solvent as described elsewhere herein.
• silvestrol-linker intermediate is dissolved to a concentration of about 5 mM, 10 mM, about 20 mM, about 30 mM, about 40 mM or about 50 mM, and ranges thereof such as from about 50 mM to about 50mM or from about 10 mM to about 30 mM in pH 8 Tris buffer (e.g., 50 mM Tris).
• silvestrol-linker intermediate is dissolved in DMSO or acetonitrile, or in DMSO. In the conjugation reaction, an equivalent excess of silvestrol-linker intermediate solution is diluted and combined with chilled antibody solution (e.g. from about 1°C to about 10°C).
• the silvestrol-linker intermediate solution may suitably be diluted with at least one polar aprotic solvent and at least one polar protic solvent, examples of which include water, methanol, ethanol, n-propanol, and acetic acid.
• the silvestrol-linker intermediate is dissolved in DMSO and diluted with acetonitrile and water prior to admixture with the antibody solution.
• the equivalents of silvestrol to antibody may suitably be about 1.5: 1, about 3: 1, about 5: 1, about 10: 1 about 15: 1 or about 20: 1, and ranges thereof, such as from about 1.5: 1 to about 20: 1 from about 1.5: 1 to about 15: 1 , from about 1.5 : 1 to about 10: l,from about 3: 1 to about 15: 1 , from about 3 : 1 to about 10: 1 , from about 5: 1 to about 15 : 1 or from about 5 : 1 to about 10: 1.
• the reaction may suitably be monitored for completion by methods known in the art, such as LC-MS (as described elsewhere herein), and the reaction is typically complete in from about 1 hour to about 24 hours.
• a reagent is added to the reaction mixture to quench the reaction and cap unreacted antibody thiol groups.
• An example of a suitable reagent is ethylmaleimide.
• the antibody-silvestrol conjugates may be purified and separated from unconjugated reactants and/or conjugate aggregates by purification methods known in the art such as, for example and not limited to, size exclusion chromatography, hydrophobic interaction chromatography, ion exchange chromatography, chromatofocusing, ultrafiltration, centrifugal ultrafiltration, and combinations thereof.
• purification may be preceded by diluting the antibody-silvestrol conjugate, such in 20 mM sodium succinate, pH 5.
• the diluted solution is applied to a cation exchange column followed by washing with, e.g., at least 10 column volumes of 20 mM sodium succinate, pH 5.
• the conjugate may be suitably eluted with PBS.
• the cytotoxic or cytostatic activity of an antibody-drug conjugate is measured by: exposing mammalian cells having receptor proteins, e.g. HER2, to the antibody of the ADC in a cell culture medium; culturing the cells for a period from about 6 hours to about 5 days; and measuring cell viability.
• Cell-based in vitro assays were used to measure viability (proliferation), cytotoxicity, and induction of apoptosis (caspase activation) of the ADC of the invention.
• the in vitro potency of antibody-drug conjugates was measured by a cell proliferation assay (Example 6).
• the ADC of the invention showed surprising and unexpected potency in inhibition of tumor cell proliferation. Potency of the ADC was correlated with target antigen expression of the cells.
• the tested conjugates are capable of binding to the specific antigen expressed on the surface of cells and causing the death of those cells in vitro.
• the CellTiter-Glo ® Luminescent Cell Viability Assay is a commercially available (Promega Corp., Madison, WI), homogeneous assay method based on the recombinant expression oi Coleoptera luciferase (US 5583024; US5674713; US5700670). This cell proliferation assay determines the number of viable cells in culture based on quantitation of the ATP present, an indicator of metabolically active cells (Crouch et al (1993) J. Immunol. Meth. 160:81-88; US 6602677).
• the CellTiter-Glo ® Assay was conducted in 96 well format, making it amenable to automated high-throughput screening (HTS) (Cree et al (1995) Anticancer Drugs 6:398-404).
• the homogeneous assay procedure involves adding the single reagent (CellTiter-Glo ® Reagent) directly to cells cultured in serum-supplemented medium. Cell washing, removal of medium and multiple pipetting steps are not required.
• the system detects as few as 15 cells/well in a 384-well format in 10 minutes after adding reagent and mixing.
• the cells may be treated continuously with ADC, or they may be treated and separated from ADC. Generally, cells treated briefly, i.e. 3 hours, showed the same potency effects as continuously treated cells.
• Inhibition of cell proliferation in vitro may be assayed using the CellTiter-GloTM Luminescent Cell Viability Assay, an embodiment of which is detailed as Example 6.
• Such assay determines the number of viable cells in culture based on quantitation of ATP present, which is an indication of metabolically active cells (Crouch et al. (1993) J. Immunol. Meth. 160:81-88; US 6602677).
• the assay may be conducted in 96- or 384-well format, making it amenable to automated high-throughput screening (HTS). See Cree et al. (1995) Anticancer Drugs 6:398-404.
• the assay procedure involves adding a single reagent (CellTiter-Glo ® Reagent) directly to cultured cells. This results in cell lysis and generation of a luminescent signal produced by a luciferase reaction.
• the luminescent signal is proportional to the amount of ATP present, which is directly proportional to the number of viable cells present in culture. Data can be recorded by luminometer or CCD camera imaging device.
• the luminescence output is expressed as relative light units (RLU).
• the homogeneous "add-mix-measure” format results in cell lysis and generation of a luminescent signal proportional to the amount of ATP present.
• the amount of ATP is directly proportional to the number of cells present in culture.
• the CellTiter-Glo ® Assay generates a "glow-type" luminescent signal, produced by the luciferase reaction, which has a half-life generally greater than five hours, depending on cell type and medium used. Viable cells are reflected in relative luminescence units (RLU).
• the substrate, Beetle Luciferin is oxi datively decarboxylated by recombinant firefly luciferase with concomitant conversion of ATP to AMP and generation of photons.
• ADC antibody-drug conjugate
• Mammalian cells useful for cell proliferation assays for anti- MUC16 ADC may include: (1) a MUC16 polypeptide-expressing cell line OVCAR-3; (2) a PC3 -derived cell line engineered to stably express a portion of the MUC16 polypeptide on its cell surface (PC3/MUC16); (3) the parental PC3 cell line that does not express the MUC16 polypeptide; and (4) a PC3 cell line that does not express MUC16 polypeptide but carries the vector used to drive exogenous MUC16 expression (PC3/neo).
• Figures 1 A and IB show the efficacy of antibody-drug conjugates in a plot of in vitro cell viability at 5 days versus concentrations ⁇ g/ml) of ADC in SK-BR-3 ( Figure 1A) and KPL-4 ( Figure IB) cells.
• Cells were plated in 96-well plates (SK-BR-3, 5000 cells/well; KPL-4, 1500 cells/well), and allowed to adhere overnight, conducted according to Example 6. Medium was then removed and replaced by fresh culture medium containing different concentrations of conjugate. Cell viability was measured 5 days after drug administration using Cell Titer-Glo.
• Free drug silvestrol amine (below) is inactive due to its impermeability, whereas free drug amino silvestrol analog is active (Table 7).
• 7C2 amino silvestrol analog ADC-106 is less potent than 7C2 silvestrol amine ADC- 103.
• Biphasic dose response curve is observed with 7C2 amino silvestrol analog ADC-106.
• Free drug amino silvestrol analog has pM or low nM IC5 0 s, whereas silvestrol amine free drug shows no activity due to its impermeability. Therefore it is difficult to determine if the potency difference between the two conjugates is caused by the difference of free drug potency.
• 7C2 amino silvestrol analog ADC-106 exhibits less potency in SK-BR-3 cells than KPL-4 cells, even though the free drug amino silvestrol analog has similar IC 50 values in SK-BR-3 (1.6 nM) and KPL-4 cells (1.2 nM)
• the in vivo efficacy of antibody-drug conjugates (ADC) of the invention can be measured by tumor xenograft studies in mice (Examples 7-10).
• the ADC of the invention showed surprising and unexpected, target-dependent and dose-dependent potency in inhibition of tumor growth. Efficacy of the ADC was correlated with target antigen expression of the tumor cells.
• the efficacy of antibody-drug conjugates were measured in vivo by implanting allografts or xenografts of cancer cells in rodents and treating the tumors with ADC.
• the in vivo efficacy of the ADC was measured using a transgenic explant mouse model expressing moderate to high levels of a tumor-associated antigen, including Her2- expressing KPL4, and CD22-expressing BJAB. Subjects were treated once with ADC and monitored over 3-6 weeks to measure the time to tumor doubling, log cell kill, and tumor shrinkage. Follow up dose-response and multi-dose experiments were conducted.
• the in vivo efficacy of an anti-HER2 ADC of the invention can be measured by a high expressing HER2 transgenic explant mouse model (Phillips et al (2008) Cancer Res. 68:9280-90).
• An allograft is propagated from the Fo5 mmtv transgenic mouse which does not respond to, or responds poorly to, HERCEPTIN® (Genentech, Inc.) therapy.
• Subjects are treated once or more with ADC at certain dose levels (mg/kg) and placebo buffer control (Vehicle) and monitored over two weeks or more to measure the time to tumor doubling, log cell kill, and tumor shrinkage, conducted according to Example 7.
• Figure 2 shows the efficacy of antibody-drug conjugates in a plot of the in vivo fitted tumor volume change over time in CD22-expressing Bjab-luc human xenograft model in CB- 17 Fox Chase SCID mice, conducted according to Example 9. after dosing once IV with:
• Figure 3 shows the efficacy of antibody-drug conjugates in a plot of the in vivo fitted tumor volume change over time in HER2-expressing KPL4 human mammary xenograft model in scid beige mice, conducted according to Example 10.
• ADC-103 compared to the vehicle and off-target control ADC-104.
• ADC-103 dosed at 1 and 3 mg/kg shows moderate activity and 6 and 10 mg/kg are around stasis.
• As a safety signal no body weight loss seen.
• Figure 4 shows the efficacy of antibody-drug conjugates in a plot of the in vivo fitted tumor volume change over time in CD-22 expressing, Bjab-luc human xenograft model in CB-17 Fox Chase SCID mice.
• Plasma for stability analysis was collected from Group 7 (10 mg/kg dose Thio CD22 HC-A140C-MC-vc-PAB-amino-Silvestrol, ADC-105) at Day 1, 3, and 7.
• Figure 5 shows the efficacy of antibody-drug conjugates in a plot of the in vivo fitted tumor volume change over time in CD-22 expressing, Bjab-luc human xenograft model in CB-17 Fox Chase SCID mice.
• the silvestrol amine ADC-110 gave moderate response at 10 mg/kg (Group 4) resulting in 81% tumor growth inhibiton at day 20.
• the amino silvestrol ADC-108 gave complete tumor regression at 3 mg/kg (Group 8).
• the efficacy was dose- dependent with lower doses giving less response.
• the efficacy was also target-specific as there was separation between the targeted CD22 ADCs, ADC-108 and ADC-110, and both non-target (LY6E) control ADCs, ADC-109 (Group 5) and ADC-107 (Group 10).
• compositions of therapeutic antibody-drug conjugates of the invention are typically prepared for parenteral administration, i.e. bolus, intravenous, intratumor injection in a unit dosage injectable form with the desired degree of purity and with one or more optional pharmaceutically acceptable carriers, excipient, and/or vehicles ⁇ Remington's Pharmaceutical Sciences 16th edition, Osol, A. Ed. (1980)), in the form of lyophilized formulations or aqueous solutions.
• Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol;
• buffers such as phosphate, citrate, and other organic acids
• antioxidants including ascorbic acid and methionine
• preservatives such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parab
• resorcinol cyclohexanol; 3-pentanol; and m-cresol
• low molecular weight polypeptides polypeptides
• proteins such as serum albumin, gelatin, or immunoglobulins
• hydrophilic polymers such as polyvinylpyrrolidone
• amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine
• chelating agents such as EDTA
• sugars such as sucrose, mannitol, trehalose or sorbitol
• salt-forming counter-ions such as sodium
• metal complexes e.g.
• sHASEGP soluble neutral-active hyaluronidase glycoproteins
• rHuPH20 HYLENEX®, Baxter International, Inc.
• a sHASEGP is combined with one or more additional glycosaminoglycanases, such as chondroitinases.
• Exemplary lyophilized antibody or immunoconjugate formulations are described in US 6267958.
• Aqueous antibody or immunoconjugate formulations include those described in US 6171586 and WO 2006/044908, the latter formulations including a histidine-acetate buffer.
• the formulation herein may also contain more than one active ingredient as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other.
• Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example,
• microcapsules respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in
• sustained-release preparations may be prepared. Suitable examples of sustained- release preparations include semipermeable matrices of solid hydrophobic polymers containing the antibody or immunoconjugate, which matrices are in the form of shaped articles, e.g. films, or microcapsules.
• the formulations to be used for in vivo administration are generally sterile. Sterility may be readily accomplished, e.g. , by filtration through sterile filtration membranes.
• the antibody-drug conjugates of the present invention may be used to treat various diseases or disorders, e.g. characterized by the overexpression of a tumor antigen.
• exemplary conditions or hyperproliferative disorders include benign or malignant solid tumors and hematological disorders such as leukemia and lymphoid malignancies.
• Others include neuronal, glial, astrocytal, hypothalamic, glandular, macrophagal, epithelial, stromal, blastocoelic, inflammatory, angiogenic and immunologic, including autoimmune, disorders.
• an antibody-drug conjugate provided herein is used in a method of inhibiting proliferation of a cancer cell, the method comprising exposing the cell to the antibody-drug conjugate under conditions permissive for binding of the antibody or antibody- drug conjugates to a tumor-associated antigen on the surface of the cell, thereby inhibiting the proliferation of the cell.
• the method is an in vitro or an in vivo method.
• the cell is a lymphocyte, lymphoblast, monocyte, or myelomonocyte cell.
• an antibody-drug conjugate for use as a medicament is provided.
• an antibody-drug conjugate for use in a method of treatment is provided.
• an antibody-drug conjugate for use in treating cancer is provided.
• the invention provides an antibody-drug conjugate for use in a method of treating an individual comprising administering to the individual an effective amount of the antibody-drug conjugate.
• the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g. , as described herein.
• the invention provides for the use of an antibody-drug conjugate in the manufacture or preparation of a medicament.
• the medicament is for treatment of cancer, the method comprising administering to an individual having cancer an effective amount of the medicament.
• the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, e.g. , as described herein.
• the invention provides a method for treating cancer.
• the method comprises administering to an individual having such cancer, characterized by detection of a tumor-associated expressing antigen, an effective amount of an antibody-drug conjugate of the invention.
• the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent, as described herein.
• Antibody-drug conjugates of the invention can be used either alone or in combination with other agents in a therapy.
• an antibody-drug conjugate of the invention may be co-administered with at least one additional therapeutic agent, such as a chemotherapeutic agent.
• Such combination therapies noted herein encompass combined administration (where two or more therapeutic agents are included in the same or separate formulations), and separate administration, in which case, administration of the antibody-drug conjugate of the invention can occur prior to, simultaneously, and/or following, administration of the additional therapeutic agent and/or adjuvant.
• Antibody-drug conjugates of the invention can also be used in combination with radiation therapy.
• Antibody-drug conjugates of the invention can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration.
• Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the administration is brief or chronic.
• Various dosing schedules including but not limited to single or multiple administrations over various time- points, bolus administration, and pulse infusion are contemplated herein.
• Antibody-drug conjugates of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
• the antibody-drug conjugate need not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody-drug conjugate present in the formulation, the type of disorder or treatment, and other factors discussed herein. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99% of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.
• an antibody-drug conjugate of the invention when used alone or in combination with one or more other additional therapeutic agents, will depend on the type of disease to be treated, the type of antibody or immunoconjugate, the severity and course of the disease, whether the antibody- drug conjugate is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to antibody-drug conjugate, and the discretion of the attending physician.
• the antibody-drug conjugate is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 ⁇ g/kg to 15 mg/kg (e.g.
• 0.1 mg/kg- lOmg/kg) of antibody-drug conjugate can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion.
• One typical daily dosage might range from about 1 ⁇ g/kg to 100 mg/kg or more, depending on the factors mentioned herein.
• the treatment would generally be sustained until a desired suppression of disease symptoms occurs.
• One exemplary dosage of the antibody-drug conjugate would be in the range from about 0.05 mg/kg to about 10 mg/kg.
• one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient.
• Such doses may be administered intermittently, e.g. every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody).
• An initial higher loading dose, followed by one or more lower doses may be administered.
• other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.
• Intracellular release of silvestrol from the antibody-silvestrol conjugate in a target cell is believed to result from cleavage of the linker unit to release an active silvestrol moiety, such as reductive cleavage of a disulfide linker bond by glutathione or protease cleavage of a peptide or peptidomimetic unit.
• Glutathione-mediated release provides for advantages as compared to certain linkers known in the prior art, such as acid-labile hydrazine linkers.
• an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described herein comprises a container and a label or package insert on or associated with the container.
• Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc.
• the containers may be formed from a variety of materials such as glass or plastic.
• the container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the disorder and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic inj ection needle).
• At least one active agent in the composition is an antibody-drug conjugate of the invention.
• the label or package insert indicates that the composition is used for treating the condition of choice.
• the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody-drug conjugate of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent.
• the article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition.
• the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for inj ection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.
• a pharmaceutically-acceptable buffer such as bacteriostatic water for inj ection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution.
• BWFI bacteriostatic water for inj ection
• phosphate-buffered saline such as bacteriostatic water for inj ection (BWFI), phosphate-buffered saline, Ringer's solution or dextrose solution.
• BWFI bacteriostatic water for inj ection
• Step 2 Preparation of (S)-l-(l-(4-(hydroxymethyl)phenylamino)-l-oxo-5- ureidopentan-2-ylcarbamoyl)cyclobutanecarboxylic acid 10b
• a coupling reagent such as TBTU (0-(Benzotriazol-l -yl)-N,N,N',N- tetramethyluronium tetrafluoroborate, also called: N,N,N' N'-Tetramethyl-0-(benzotriazol-l- yl)uronium tetrafluoroborate, CAS No.
• Step 3 Preparation of S)-N-(5-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l-yl)pentyl)- N-(l-(4-(hydroxymethyl)phenylamino)-l-oxo-5-ureidopentan-2-yl)cyclobutane-l,l- dicarboxamide 10
• Step 4 Preparation of (S)-N-(l-(4-(chloromethyl)phenylamino)-l-oxo-5- ureidopentan-2-yl)-N-(5-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l -yl)pentyl)cyclobutane-l,l- dicarboxamide 11
• Step 5 Preparation of (S)-4-(2-(l-(5-(2,5-dioxo-2,5-dihydro-lH-pyrrol-l- yl)pen ⁇ ylcarbamoyl)cyclobutanecarboxamido)-5-ureidopentanamido)benzyl 4-nitrophenyl carbon
• Step 7 Preparation of 2,5-dioxopyrrolidin-l -yl l-((5-(2,5-dioxo-2,5-dihydro- -pyrrol-1 -yl)pentyl)carbamoyl)cyclobutanecarboxylate 15
• Step 8 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6R)-6-((4R)-2-
• Step 9 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6R)-6-((4R)-2-
• Step 10 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6R)-6-((4R)-2- (4-((S)-2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-5-ureidopentanamido)phenyl)-l,3- dioxolan-4-yl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8-methoxy-3a-(4- enyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2-carboxylate
• Step 11 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6R)-6-((4R)-2-
• Step 1 Preparation of (lR,2R,3S,3aR,8bS)-6-(((2S,3R,6R)-6-((R)-l ,2- dihydroxyethyl)-3-methoxy-l ,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8-methoxy-3a-(4- methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2-carboxylic acid 20
• Step 3 Preparation of (9H-fluoren-9-yl)methyl (2-((lR,2R,3S,3aR,8bS)-6- (((2S,3R,6R)-6-((R)-l,2-dihydroxyethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8- methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran- 2-carboxamido)ethyl)carbamate 21
• Step 4 Preparation of (lR,2R,3S,3aR,8bS)-N-(2-aminoethyl)-6-(((2S,3R,6R)-
• Tetrabutylammonium iodide (471 mg, 1.27 mmol) and methyl 2-bromo-2- methoxyacetate (2.05 g, 11.21 mmol) were then added and the resulted reaction mixture was stirred for an additional 2 h at 120 °C.
• Step 2 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6S)-6-(2- (benzyloxy)ethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8-methoxy-3a-(4- methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2-carboxylate 25
• Step 3 Preparation of (lR,2R,3S,3aR,8bS)-methyl l,8b-dihydroxy-6-
• Step 4 Preparation of (lR,2R,3S,3aR,8bS)-methyl l,8b-dihydroxy-8- methoxy-6-(((2S,3R,6S)-3-methoxy-6-(2-((methylsulfonyl)oxy)ethyl)-l,4-dioxan-2-yl)oxy)- 3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2- carboxylate 27
• Step 5 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6S)-6-(2- azidoethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8-methoxy-3a-(4- methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2-carboxylate 28
• Step 6 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6S)-6-(2- aminoethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8-methoxy-3a-(4- methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2-carboxylate 29
• Step 1 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6S)-6-(2-
• Step 2 Preparation of (lR,2R,3S,3aR,8bS)-methyl l,8b-dihydroxy-6-
• Step 1 Preparation of (lR,2R,3S,3aR,8bS)-2,5-dioxopyrrolidin-l-yl 6-
• Step 2 Preparation of (lR,2R,3S,3aR,8bS)-6-(((2S,3R,6R)-6-((R)-l ,2- dihydroxyethyl)-3-methoxy-l ,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-N-(2-mercaptoethyl)-8- methoxy-3a-(4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran- 2-carboxamide 33
• Step 1 Preparation of methyl (lR,2R,3S,3aR,8bS)-6-(((2S,3R,6R)-6-((R)-2-
• Step 2 Preparation of (lR,2R,3S,3aR,8bS)-methyl 6-(((2S,3R,6R)-6-((R)-l,2- dihydroxyethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8-methoxy-3a-(4- methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2-carboxylate 16
• tetrabutyl ammonium fluoride (TBAF, 125.97 mg, 0.480 mmol).
• the reaction mixture was stirred at 25 °C for 12 h.
• the reaction mixture was quenched with water (20 mL), and extracted with EtOAc (10 mL X 2).
• the combined organic layers were washed with brine (20 mL), dried over Na 2 S0 4 , and concentrated in vacuo.
• Step 3 Preparation of (lR,2R,3S,3aR,8bS)-6-(((2S,3R,6R)-6-((R)-l,2- dihydroxyethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l,8b-dihydroxy-8-methoxy-3a-(4- methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2-carboxylic acid 20
• Step 5 Preparation of (lR,2R,3S,3aR,8bS)-N-(2-aminoethyl)-6-(((2S,3R,6R)- 6-((R)-l,2-dihydroxyethyl)-3-methoxy-l,4-dioxan-2-yl)oxy)-l ,8b-dihydroxy-8-methoxy-3a- (4-methoxyphenyl)-3-phenyl-2,3,3a,8b-tetrahydro-lH-cyclopenta[b]benzofuran-2- carboxamide 21a
• VL and VH were transfected into CHO cells and IgG was purified from cell culture media by protein A affinity chromatography.
• the engineered cysteine residues in antibodies exist as mixed disulfides with cellular thiols (e.g., glutathione) and are thus unavailable for conjugation. Partial reduction of these antibodies (e.g., with DTT), purification, and reoxidation with dehydroascorbic acid (DHAA) gives antibodies with free cysteine sulfhydryl groups available for conjugation, as previously described, e.g., in Junutula et al. (2008) Nat. Biotechnol.
• DHAA dehydroascorbic acid
• cysteine engineered antibodies were made reactive for conjugation with drugs by treatment with a reducing agent such as DTT (Cleland's reagent, dithiothreitol) or TCEP (tris(2-carboxyethyl)phosphine hydrochloride; Getz et al. (1999) Anal. Biochem. Vol 273:73-80; Soltec Ventures, Beverly, MA) in 50 mM Tris pH 7.5 with 2 mM EDTA for 3 hrs at 37°C or overnight at room temperature.
• a reducing agent such as DTT (Cleland's reagent, dithiothreitol) or TCEP (tris(2-carboxyethyl)phosphine hydrochloride; Getz et al. (1999) Anal. Biochem. Vol 273:73-80; Soltec Ventures, Beverly, MA) in 50 mM Tris pH 7.5 with 2 mM EDTA for 3 hrs at 37°C or
• the reduced THIOMABTM was diluted and loaded onto a HiTrap S column in 10 mM sodium acetate, pH 5, and eluted with PBS containing 0.3M sodium chloride.
• the antibody was acidified by addition of l/20 th volume of 10% acetic acid, diluted with 10 mM succinate pH 5, loaded onto the column and then washed with 10 column volumes of succinate buffer. The column was eluted with 50 mM Tris pH7.5, 2 mM EDTA.
• Light chain amino acids are numbered according to Kabat (Kabat et al, Sequences of proteins of immunological interest, (1991) 5th Ed., US Dept of Health and Human Service, National Institutes of Health, Bethesda, MD). Heavy chain amino acids are numbered according to the EU numbering system (Edelman et al. (1969) Proc. Natl. Acad, of Sci.
• THIOMABTM Full length, cysteine engineered monoclonal antibodies (THIOMABTM) expressed in CHO cells bear cysteine adducts (cystines) or glutathionylated on the engineered cysteines due to cell culture conditions.
• cysteine adducts cysteine adducts
• glutathionylated glutathionylated on the engineered cysteines due to cell culture conditions.
• the THIOMABTM was dissolved in 500 mM sodium borate and 500 mM sodium chloride at about pH 8.0 and reduced with about a 50-100 fold excess of 1 mM TCEP (tris(2- carboxyethyl)phosphine hydrochloride (Getz et al. (1999) Anal. Biochem.
• THIOMABTM by carrying out reoxidation.
• the eluted reduced THIOMABTM was treated with 15X or 2 mM dehydroascorbic acid (dhAA) at pH 7 for about 3 hours or for about 3 hrs in 50 mM Tris-Cl, pH 7.5, or with 200 nM to 2 mM aqueous copper sulfate (CUSO4) at room temperature overnight.
• Other oxidants, i.e. oxidizing agents, and oxidizing conditions, which are known in the art may be used.
• Ambient air oxidation may also be effective. This mild, partial reoxidation step formed intrachain disulfides efficiently with high fidelity.
• the buffer was exchanged by elution over Sephadex G25 resin and eluted with PBS with lmM DTP A.
• the thiol/ antibody value was checked by determining the reduced antibody concentration from the absorbance at 280 nm of the solution and the thiol concentration by reaction with DTNB (Aldrich, Milwaukee, WI) and determination of the absorbance at 412 nm.
• Liquid chromatography /Mass Spectrometric Analysis was performed on a TSQ Quantum Triple quadrupoleTM mass spectrometer with extended mass range (Thermo Electron, San Jose California). Samples were chromatographed on a PRLP-S®, 1000 A, microbore column (50mm x 2.1mm, Polymer Laboratories, Shropshire, UK) heated to 75 °C. A linear gradient from 30-40% B (solvent A: 0.05% TFA in water, solvent B: 0.04% TFA in acetonitrile) was used and the eluent was directly ionized using the electrospray source. Data was collected by the Xcalibur® data system and deconvolution was performed using
• HIC Hydrophobic Interaction Chromatography
• Chemstation software was used to resolve and quantitate antibody species with different ratios of drugs per antibody.
• cysteine-engineered antibody THIOMABTM
• PBS phosphate buffered saline
• PBS phosphate buffered saline
• bromoacetamide is dissolved in DMSO, diluted in acetonitrile and water, and added to the chilled, reduced, and reoxidized antibody in PBS.
• the drug is added from a DMSO stock at a concentration of about 20 mM in 50 mM Tris, pH 8, to the antibody and monitored until the reaction is complete from about 1 to about 24 hours as determined by LC-MS analysis of the reaction mixture.
• a capping reagent such as ethyl maleimide is added to quench the reaction and cap any unreacted antibody thiol groups.
• the conjugation mixture may be loaded and eluted through a HiTrap SP FF column to remove excess drug and other impurities.
• the reaction mixture is concentrated by centrifugal ultrafiltration and the cysteine engineered antibody-drug conjugate is purified and desalted by elution through G25 resin in PBS, filtered through 0.2 ⁇ filters under sterile conditions, and frozen for storage.
• the crude antibody-drug conjugate is applied to a cation exchange column after dilution with 20 mM sodium succinate, pH 5.
• the column was washed with at least 10 column volumes of 20 mM sodium succinate, pH 5, and the antibody was eluted with PBS.
• the antibody-drug conjugates were formulated into 20 mM His/acetate, pH 5, with 240 mM sucrose using gel filtration columns.
• the antibody-drug conjugates were characterized by UV spectroscopy to determine protein concentration, analytical SEC (size-exclusion chromatography) for aggregation analysis and LC-MS before and after treatment with Lysine C endopeptidase.
• Size exclusion chromatography is performed using a Shodex KW802.5 column in 0.2M potassium phosphate pH 6.2 with 0.25 mM potassium chloride and 15% IPA at a flow rate of 0.75 ml/min. Aggregation state of the conjugate was determined by integration of eluted peak area absorbance at 280 nm.
• LC-MS analysis may be performed using an Agilent QTOF 6520 ESI instrument.
• the antibody-drug conjugate is treated with 1 :500 w/w Endoproteinase Lys C (Promega) in Tris, pH 7.5, for 30 min at 37°C.
• the resulting cleavage fragments are loaded onto a lOOOA (Angstrom), 8 ⁇ (micron) PLRP-S (highly cross-linked polystyrene) column heated to 80 °C and eluted with a gradient of 30% B to 40% B in 5 minutes.
• Mobile phase A was H 2 0 with 0.05% TFA and mobile phase B was acetonitrile with 0.04% TFA.
• the flow rate was 0.5ml/min.
• Protein elution was monitored by UV absorbance detection at 280nm prior to electrospray ionization and MS analysis. Chromatographic resolution of the unconjugated Fc fragment, residual unconjugated Fab and drugged Fab was usually achieved. The obtained m/z spectra were deconvoluted using Mass HunterTM software (Agilent Technologies) to calculate the mass of the antibody fragments.
• Efficacy of the antibody-drug conjugates Thio Hu Anti-CD22 10F4v3 LC K149C silvestrol and Thio Hu Anti-Ly6E 9B12.vl2 LC K149C silvestrol was measured by a cell proliferation assay employing the following protocol (CELLTITER GLOTM Luminescent Cell Viability Assay, Promega Corp. Technical Bulletin TB288; Mendoza et al. (2002) Cancer Res. 62:5485-5488): 1.
• Control wells were prepared containing medium and without cells.
• the plate was incubated at room temperature for 5 minutes to stabilize the luminescence signal.
• Luminescence was recorded and reported in graphs as % activity where RLU (relative luminescence units) was normalized to controls (no antibody control minus no cell control).
• the protocol is a modification of the CELLTITER GLOTM Luminescent Cell.
• Media: BJAB, WSU-DLCL2, and Jurkat may be grown in media including RPMI-1640, 20% HI-FBS, 2mM L-Glutamine.
• the Fo5 mouse mammary tumor model is employed to evaluate the in vivo efficacy of antibody-drug conjugates of the invention after single dose intravenous injections, and as described previously (Phillips GDL, Li GM, Dugger DL, et al. Targeting HER2 -Positive Breast Cancer with Trastuzumab-DMl, an Antibody-Cytotoxic Drug Conjugate. (2008) Cancer Res. 68:9280-90), incorporated by reference herein.
• Anti-Her2 antibody-drug conjugates may be tested with the Fo5 model, a transgenic mouse model in which the human HER2 gene is over-expressed in mammary epithelium under transcriptional regulation of the murine mammary tumor virus promoter (MMTV-HER2).
• the HER2 over-expression causes spontaneous development of a mammary tumor.
• the mammary tumor of one of these founder animals (founder #5 [Fo5]) is propagated in subsequent generations of FVB mice by serial transplantation of tumor fragments (- 2 x 2 mm in size). All studies are conducted in accordance with the Guide for the Care and Use of Laboratory Animals.
• Each antibody-drug conjugate (single dose) is dosed in nine animals intravenously at the start of the study, and 14 days post-transplant.
• Initial tumor size is about 200 mm 3 volume.
• mammary fat pad transplant efficacy models may be employed as described (Chen et al. (2007) Cancer Res 67:4924-4932), evaluating tumor volume after a single intravenous dose and using tumors excised from a mouse bearing an intraperitoneal tumor, then serially passaged into the mammary fat pads of recipient mice.
• HCC1569 (CRL-2330) was obtained from American Type Culture Collection (ATCC, Manassas, VA).
• the HCC1569 X2 cell line is a derivative of the parental HCC1569 cell line (ATCC, CRL-2330) optimized for growth in vivo. Parental
• HCC1569 cells were injected subcutaneously in the right flank of female SCID Beige mice, one tumor was harvested, minced and grown in vitro resulting in a HCC1569 XI cell line.
• the HCC1569 XI line was injected again subcutaneously in the right flank of female SCID Beige mice in an effort to improve the growth of the cell line.
• a tumor from this study was collected and again adapted for in vitro growth to generate the HCC1569 X2 cell line. This cell line and tumors derived from this line express Ly6E.
• SCID Beige mice were inoculated with about 2 million cells in histidine buffer #8 vehicle.
• tumor volumes reached approximately 80-200 mm 3 (day 0)
• the animals were randomized into groups of about 6 to 10 each, and administered a single intravenous (IV) injection of either vehicle control or an antibody-drug conjugate at the following doses: 0.3 mg/kg, 1 mg/kg/ 3 mg/kg, 6 mg/kg and 10 mg/kg.
• Example 7 Efficacy of Thio anti-CD22 LC-K149C-MC-vc-PAB-Silvestrol-amine in Bjab-luc human xenograft model in CB-17 Fox Chase SCID mice.
• Example 8 Efficacy of Thio anti-Her2 7C2 LC-K149C-MC-vc-PAB-Silvestrol- amine in KPL4 human mammary xenograft model in scid beige mice.
• HBSS/matrigel in the thoracic 2/3 mammary fat pad at a volume of 0.2 ml.
• tumors When tumors have reached a mean tumor volume of 150-250 mm3, they will be grouped out into 8 groups of 5 mice each. Single treatments will be administered on Day 0. Volume not to exceed 0.2 ml, needle size 28 or 29 gauge.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Epidemiology (AREA)
• Immunology (AREA)
• Cell Biology (AREA)
• Biochemistry (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Biophysics (AREA)
• Oncology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Genetics & Genomics (AREA)
• Food Science & Technology (AREA)
• Biotechnology (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Microbiology (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Peptides Or Proteins (AREA)
• Medicinal Preparation (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Plural Heterocyclic Compounds (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (3)

Applications Claiming Priority (2)

Publications (1)

Family

ID=59071109

Family Applications (1)

Country Status (5)

Cited By (4)

Families Citing this family (5)

Citations (316)

Family Cites Families (13)

• 2017
  • 2017-06-05 CN CN201780043931.1A patent/CN109476648B/zh active Active
  • 2017-06-05 JP JP2018563547A patent/JP7043425B2/ja active Active
  • 2017-06-05 EP EP17731020.8A patent/EP3464280B1/en active Active
  • 2017-06-05 WO PCT/US2017/035925 patent/WO2017214024A1/en not_active Ceased
  • 2017-06-05 US US15/613,477 patent/US10639378B2/en active Active
• 2020
  • 2020-03-23 US US16/827,083 patent/US11648315B2/en active Active

Patent Citations (338)